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The National Drug-Related Deaths Index (NDRDI) 
reports on poisoning deaths (also known as 
overdose), which are deaths in the general 
population due to the toxic effect of a drug or 
combination of drugs, and on non-poisonings, 
which are deaths as a result of trauma, such as 
hanging, or medical reasons, such as cardiac events, 
among people who use drugs. The latest figures 
from the NDRDI show that 376 people died in 2017 
from poisoning deaths and that 410 non-poisoning 
deaths occurred among people who used drugs.1,2
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In brief
Whatever type of government emerges in the aftermath of 
Election 2020, one peculiarity of Irish political governance will 
not be changed during the lifetime of the 33rd Dáil – Ireland is 
a very centralised country and the responsibilities and power 
of local government have gradually decreased over several 
decades. 
This imbalance is somewhat offset by the part played by civil society in both 
the delivery of services and contributing to policy development in many areas. 
Non-governmental organisations, community groups, church-owned or other 
faith-based organisations have historically played prominent roles in the health, 
social protection, and education spheres. The State has accommodated this 
reality for both political and fiscal reasons. In turn, civil society organisations 
have taken the opportunity presented by this role to lobby for sectoral 
concerns and to advocate on behalf of those citizens for whom it provides 
services.
A partnership approach, supporting the involvement of the non-governmental 
sector in both policy development and service delivery, has long been a feature 
of Irish drugs policy. The establishment of drug taskforces in the 1990s was an 
acknowledgment both of the valuable work being done at community level 
and the importance of communities as a source of knowledge in developing 
responsive, effective, and well-supported policies. The European Commission 
identifies civil society involvement as key to the implementation of drugs policy 
that is both well informed and capable of earning legitimacy. A comparative 
study in 2018 found that the level of this involvement was high in Ireland and 
that this country did not have to face the difficulties encountered by non-
governmental entities in other countries.1
While this study found that there was a need for greater practical support 
and care as regards involvement of civil society in key decisions, it was also 
clear that the new drugs strategy had been well received by community and 
voluntary actors and has structures in place to support their participation. A 
2020 paper describes the partnership approach underpinning the preparation 
of the national drugs strategy during 2016 and 2017 and the consensus-based 
approach to deciding on strategic actions.2 Decisions followed what the paper 
described as ‘robust’ debate, which ensured that all voices had an equal 
opportunity to be heard.
It is somewhat ironic that in the two areas identified as being of particular 
concern to the electorate, housing and health, local involvement in decision-
making is very low compared with a generation ago. The end of the health 
boards and the very limited involvement of local authorities in housing 
provision has removed a layer of governance that, while problematic at times, 
was at least capable of responding to local concerns and could be useful in 
coordinating public service at regional or lower level. In the drugs field, we 
have a robust voluntary sector with great expertise and policy knowledge in low 
threshold, residential, and harm reduction work. Taskforces are responsible 
for developing a response tailored to the region or urban area in which they 
operate and for bringing community representatives together to ensure that 
this response is suitable, has broad support, and is effective. This model of 
civil society engagement is one that could provide useful pointers on findings 
solutions to other societal problems. 
 
1 Lahusen H, Verthein U and Martens M-S (2018) Civil society involvement in drug 
policy in EU member states. Assessment report. Amsterdam: De Regenboog Groep/
Correlation Network. https://www.drugsandalcohol.ie/29890/
2 Comiskey C (2020) Reducing harm, supporting recovery: a partnership and 
evidence-informed approach to developing the new Irish health led, National Drug 
Strategy. Harm Reduct J, 17(1): 3. https://www.drugsandalcohol.ie/31534/
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Key findings
Key findings of the report are:
• Taking a cocktail of drugs (polydrugs) continues to be a 
significant factor in poisoning deaths, contributing to 3 in 5 
poisoning deaths.
• There is an increase in cocaine poisoning deaths. 
• Alcohol continues to be the main drug implicated in 
poisoning deaths, alone or with other drugs.
• Hanging is the main cause of non-poisoning deaths.
Deaths in 2017 among people who inject drugs
People who were injecting at the time of the incident that 
led to their death represented 4% (n=34) of all drugs-related 
deaths in 2017. The majority were male and involved opioids 
(94%). Two in five (41%) occurred in Dublin city and the majority 
were alone at the time of injecting (see Figure 1).
Poisoning deaths in 2017
The annual number of poisoning deaths increased by 2% from 
368 in 2016 to 376 in 2017. As in previous years, the majority 
(70%) were male. The median age of those who died was 43 
years (see Figure 2).
Key findings of poisoning deaths in 2017:
• Alcohol was implicated in over 1 in 3 poisoning deaths (33%) 
and alcohol alone was responsible for 16% of all poisoning 
deaths (see Figure 3).
• Opioids were the main drug group implicated in poisonings; 
methadone was implicated in one-quarter (25%) of 
poisonings, while heroin-related poisoning deaths increased 
from 74 deaths in 2016 to 77 in 2017.
• Prescribable (prescription and/or over-the-counter) drugs 
were implicated in 2 in every 3 (67%) poisoning deaths.
       –   Benzodiazepines were the most common prescribable 
drug group implicated. Diazepam was the most common 
benzodiazepine-type drug and was implicated in 1 in 4 
(90; 24%) of poisonings.
       –   Methadone was the most common individual 
prescribable drug implicated in 95 (25%) poisonings 
deaths.
       –   Alprazolam poisoning deaths increased by 34% from 47 
in 2016 to 63 in 2017.
• Cocaine-related deaths increased from 42 in 2016 to 53 in 
2017.
• MDMA-related deaths increased from 8 in 2016 to 14 in 2017.
Drug-related deaths, 2008-2017   
continued
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Figure 2: Infographic of poisoning deaths in 2017
Figure 1: Infographic of all deaths among people known to be injecting at time of death in 2017
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Polydrug poisonings in 2017
Taking a cocktail of drugs (polydrugs) can increase the risk of 
fatal overdose. The majority of poisoning deaths (58%) in 2017 
involved polydrugs, with an average of four different drugs 
taken (see Figure 4).
• 51% (64) of deaths where alcohol was implicated involved 
other drugs, mainly opioids.
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Figure 4: Evolution of polydrug poisonings, NDRDI, 2008-2017 (n=3715)
Figure 3: Infographic of drugs implicated in poisoning deaths in 2017
• 89% (85) of deaths where methadone was implicated 
involved other drugs, mainly benzodiazepines.
• 86% (66) of deaths where heroin was implicated involved 
other drugs, mainly benzodiazepines.
• All diazepam-related poisoning deaths (90) involved other 
drugs, mainly opioids.
• All alprazolam-related poisoning deaths (63) involved other 
drugs, mainly opioids. 
Non-poisoning deaths in 2017
The number of non-poisoning deaths increased slightly, with 
410 deaths in 2017 compared with 404 in 2016. Non-poisoning 
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Drug-related deaths, 2008-2017   
continued
POLICY AND LEGISLATION 
British–Irish  
Council in Dublin
On 15 November 2019, the 33rd British–Irish Council (BIC) 
summit was held in Dublin, part of which consisted of a 
ministerial meeting on health and social initiatives that relate 
to substance misuse. An Taoiseach Leo Varadkar hosted the 
summit at Farmleigh House in Dublin, with administration heads 
from Scotland, Wales, the Isle of Man, Jersey, Guernsey, and the 
British Government.1
The BIC was established in 1999 as part of the Good Friday 
Agreement in order to further promote positive, practical 
relationships among the people of the islands as well as to 
provide a forum for consultation and cooperation.
The formal purpose of BIC, as outlined in Strand 3 of the 
Agreement, is:
To promote the harmonious and mutually beneficial 
development of the totality of relationships among 
the peoples of these islands.... The BIC will exchange 
information, discuss, consult and use best endeavours 
to reach agreement on co-operation on matters of 
mutual interest within the competence of the relevant 
Administrations.2
The BIC covers a number of formal areas of work, including the 
misuse of substances, for which the Irish Government is the 
lead administration. 
As part of the summit, Minister for Health Simon Harris TD and 
Minister of State for Health Promotion and the National Drugs 
Strategy Catherine Byrne TD hosted a discussion on substance 
misuse with those responsible for health policy from the various 
delegations. The discussion explored the links between health 
and social initiatives and community policing as well as their 
long-term social and economic benefits to communities.
Participants shared experiences of initiatives within their own 
administrations. Participants from the travelling delegations also 
visited the Dublin North East Inner City Inclusion Health Hub. 
The hub houses a specialised general practitioner and nursing 
practice; the Health Service Executive Homeless Health-Link 
Team; the Homeless and Addiction Case Management Teams; 
and specialist maternity services for women in addiction.
More details on the work of the BIC is available from its website: 
https://www.britishirishcouncil.org/
Lucy Dillon
1 British–Irish Council (2019) 33rd British–Irish Council Summit, 
Dublin: 15 November 2019 – Communiqué. Edinburgh: British–Irish 
Council. https://www.drugsandalcohol.ie/31383/
2 A copy of the Good Friday Agreement can be found at https://
www.dfa.ie/media/dfa/alldfawebsitemedia/ourrolesandpolicies/
northernireland/good-friday-agreement.pdf
At the British–Irish Council summit in Dublin in November 2019 
were (L to R) Minister of State for Health Promotion and the 
National Drugs Strategy, Catherine Byrne TD; Joe FitzPatrick MSP, 
Minister for Public Health, Sport and Wellbeing in the Scotland 
Government; Deputy Heidi Soulsby, President of the Committee 
for Health and Social Care in the States of Guernsey; Simon Harris 
TD, Minister for Health; Hon David Ashford MHK, Minister for 
Health and Social Care in the Isle of Man; Baroness Blackwood, 
Parliamentary Under Secretary of State at the Department of 
Health and Social Care in the UK; and Julie Morgan AM, Deputy 
Minister for Health and Social Services in the Welsh Government
deaths are categorised as being due to either trauma (n=196) or 
medical causes (n=214).
• The main causes of non-poisoning deaths categorised as 
trauma were hanging (114; 28%) and those categorised as 
medical were cardiac events (56; 14%).
• Six in every 10 (63%) people who died as a result of hanging 
had a history of mental health problems.
• The median age for deaths due to medical causes has 
increased from 42 years in 2008 to 49 years in 2017, which may 
indicate an ageing cohort of people who use drugs in Ireland.
Ena Lynn
1 Health Research Board (2019) National Drug-Related Deaths Index 
2008–2017 data. Dublin: Health Research Board.  
https://www.drugsandalcohol.ie/31275
2 A number of infographics that outline key data are also available 
for download as well as tables outlining breakdown by county and 
by DATFA (Drug and Alcohol Task Force Area) (https://www.hrb.ie/
publications/publication/national-drug-related-deaths-index-
2008-to-2017-data/returnPage/1/). For further information, visit: 
https://www.drugsandalcohol.ie/31275 and https://www.hrb.ie/
publications
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The theme of the 2019 National Drugs Forum was ‘Inclusion 
Health: responding to complex health needs of people who use 
drugs’. Opening the forum, Minister of State with responsibility 
for Health Promotion and the National Drugs Strategy, 
Catherine Byrne TD, said: 
There are people in our society who struggle with 
health problems but feel isolated and cannot access 
the help and support they need. Our shared goal 
must be to reach out and deliver better health 
outcomes for these people and, in particular, to make 
our health and social services more inclusive for 
those in addiction who may also have other complex 
needs.
The two keynote speakers at the forum made important 
contributions to our understanding of the concept of 
inclusion health and the practical implications of configuring 
Ireland’s healthcare services to meet the needs of its most 
vulnerable populations. Professor Andrew Hayward, director 
of UCL Institute of Epidemiology and Health Care, and Dr 
Clíona Ní Cheallaigh, consultant in infectious diseases and 
general medicine in St James’s Hospital, Dublin, shared their 
experience from clinical work and their knowledge gained from 
academic work on the impact of inequality and marginalisation 
on health.
Design thinking
Following the keynote talks, the forum participants took 
part in an exercise called Design Thinking, which was used 
to frame group discussions around a few defined problems. 
Design thinking facilitates the generation of creative, problem-
solving ideas. One of the hallmarks of the approach is that it 
is user-centred; it revolves around the needs of the individual 
service user, client, or stakeholder. The approach encourages 
divergent thinking and seeks to stimulate ideas that go beyond 
the obvious.
The participants in each group shared the knowledge and 
experience they have gained through working in various types 
National Drugs 
Forum 2019
Inclusion Health: 
Responding to Complex 
Health Needs of People 
Who Use Drugs
Croke Park Stadium
5 November 2019
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National Drugs Forum   continued
of services in an open discussion on a particular problem. 
The purpose was not necessarily to provide a solution to the 
problem, but to think creatively about it. Working through the 
problem in this way can help with the analysis of real, everyday 
problems in the workplace and provide pointers on how to 
work together with colleagues to solve them. Each group 
of forum participants worked on a particular scenario. The 
scenarios included a limited profile, or persona, of someone 
facing a particular problem. Before considering how to respond 
to the situation described in the scenario, the groups worked 
on developing the persona further to make it more meaningful.
The groups used a number of idea generation techniques to 
refine the ideas they came up with. They were asked to be 
expansive in their thinking and not to be overly concerned 
with possible obstacles or a lack of resources. There were 
five scenarios in all and, following each group’s deliberations, 
a representative from each group joined others who had 
been working on the same scenario. These participants 
then compiled a workbook, representing a distillation of the 
discussions around each particular scenario. An account of the 
work of the forum participants is presented below.
Persona needs
The needs of each persona were arranged under functional, 
social, and emotional headings. Functional supports tend to 
focus on the type of services that would enable the persona 
to better understand and manage their own situation. While 
standard healthcare, child support, and family support 
services were frequently mentioned, a number of participants 
suggested that assistance with legal issues was important. 
This should cover interaction with the criminal justice system, 
family concerns, such as child custody, and welfare matters. 
It was seen as important that the persona did not suffer 
further financial disadvantage as a result of being unaware 
of entitlements; expert advice in this regard was frequently 
mentioned as an important resource.
Participants frequently mentioned the importance of helping 
to establish or re-establish social connections. The impact of 
loneliness on the persona’s recovery capacity was frequently 
cited. Friendships and role models are important aspects of 
social support. Hobbies and sporting activities need to be 
encouraged, as these can help alleviate social isolation. Many 
of the emotional needs identified relate to, or overlap with, the 
social aspect. Negative emotions – such as guilt, shame, fear, 
anxiety, trauma, self-stigma, and hopelessness – compound 
the persona’s inability to build social connections. Reinforcing 
social values through, for instance, establishing connections 
with one’s children, was frequently referred to. Relationship 
counselling and dealing with intrapersonal problems such as 
mistrust are often needed to establish a healthy emotional 
state. Emotional barriers compound other barriers to recovery 
and the feelings of being exhausted, in emotional pain, and 
powerless require focused responses. Many participants 
emphasised the need to feel safe and one underlined the 
importance of the persona’s capacity to manage pain, restore 
autonomy, and establish feelings of self-worth.
Blue sky strategy
Under the ‘create’ heading, participants were asked to list a 
series of current activities that they would eliminate, reduce, 
or raise and identify new courses of action. The harmful 
consequences of working in silos were observed in a number 
of groups and there was an emphasis on the need for greater 
integration of services. Some noted that there was an overly 
medical approach to opiate use problems and there was a need 
to examine alternatives. Although it had already been identified 
as an issue under the ‘barriers’ heading, several groups stressed 
the importance of removing, or seeking to reduce, feelings of 
stigma among services users. From a service-level perspective, 
the time spent on administration, such as forms and dealing 
Dr Clíona Ní Cheallaigh (left), 
keynote speaker with Minister 
of State with responsibility 
for Health Promotion and 
the National Drugs Strategy, 
Catherine Byrne TD, at the 
National Drugs Forum
Dr Clíona Ní Cheallaigh
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with insurance issues, was seen as a resource that took from 
more immediate work. There is a need to avoid duplicating 
services or competing for resources.
Integration of services was a common theme under the ‘raise’ 
heading in this part of the exercise. The need to combine 
different treatment modalities and knowledge in one setting 
through multidisciplinary working in case management, 
dual diagnosis services, and early intervention for adverse 
childhood experiences was mentioned. One specific idea 
that emerged was for a special case management service 
for people with complex and multiple needs. This service 
should be available throughout the country. Allied to this 
approach was the proposal for an inclusion hub that would 
enable a multidisciplinary team to provide both mental and 
physical health services together. Alongside this need for 
more consolidation and security, the importance of national 
evaluation frameworks and the development of a more rigorous 
research community was identified.
The treatment continuum, implied in the concept of recovery, 
and the key role of service users in designing this process is 
part of the aspiration for greater integration and consolidation. 
When considering the ‘create’ heading, many participants 
suggested expansion of services in different ways, including 
out-of-hours support and working on access to services. 
Information technology was a consistent theme, with the idea 
of an information hub, the use of apps, social media, online 
information, and online diary support mentioned. The interest 
in integrating services under the ‘raise’ heading is echoed 
under support for a one-stop arrangement where all services 
are gathered together in one physical location. Although it was 
not explicitly tied to the need to lessen the burden of stigma, 
a number of participants said that decriminalisation of drug 
possession for personal use would be an important step.
Concept board
Each group was asked to arrange their responses to the 
situation faced by the persona under mild, stretch, and wild 
descriptors. Developments that need a slight adjustment in 
service delivery or additional effort on the part of policymakers 
would come under the mild category. Responses under this 
heading often mentioned family supports, which should 
include helping to deal with the young person at risk of 
deeper involvement in drug use or further harm, or preschool 
supports and the involvement of teachers in family support 
work. One suggestion was for a national community support 
service supporting community care managers. There would 
be a ‘national brand’ helping to challenge stigma and negative 
portrayals of the service user. Practical solutions such as a 
virtual hub, which would support teleconference work, was an 
idea put forward by the same group of participants. Access to 
the hub would be by self-referral and the client would identify 
their own needs. An app would give access to someone like a 
key worker regardless of where the person requiring the service 
lived. Access to a multidisciplinary team would eliminate the 
need to be physically present to avail of services.
Innovative solutions organised around families was the 
focus of some of the proposals. One was the notion of a 
‘foster family’ for families, allowing them to stabilise their 
accommodation situation or resettle. The model of the au 
pair could be used to enable a mother to work on mentoring 
and companionships, while some of the day-to-day burdens 
of domestic responsibilities were lifted. Reconnection with 
children, supported by legal services, was also mentioned. The 
idea of a ‘recovery village’ was mentioned by one group but not 
explained in detail.
Inclusion health policy
The Department of Health is currently developing an 
inclusion health policy. It is considering the international 
evidence relating to the concept and how the experience 
of implementing programmes based on inclusion health 
can inform policy in Ireland. Making use of experience and 
understanding the perspective of both service providers 
and potential service users will be a key component of the 
development of policy in this area. The ideas generated 
through the design-thinking exercise at the National Drugs 
Forum will form part of the learning on which this important 
policy initiative will be based.
Brian Galvin
At the National Drugs Forum 
in Croke Park were (L to R) Mr 
Jim Walshe, Principal Officer, 
Drugs Policy Unit, Department of 
Health; Dr Clíona Ní Cheallaigh, 
St James’s Hospital; Minister of 
State for Health Promotion and 
the National Drugs Strategy, 
Catherine Byrne TD; Dr Peter 
Robbins, Dublin City University, 
who led the design-thinking 
exercise; and Professor Andrew 
Hayward, Director of the Institute 
of Epidemiology and Health Care 
at University College London
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PREVALENCE AND CURRENT SITUATION
Drug treatment in 
Ireland 2012–2018
Published in November 2019, the latest National Drug Treatment 
Reporting System (NDTRS) drug bulletin presents trends in 
treated problem drug use (excluding alcohol) for the seven-year 
period from 2012 to 2018.1,2
Key findings
Over the period, 65,216 cases treated for problem drug use 
were reported to the NDTRS.3 In 2018, the NDTRS recorded 
10,274 treated cases, an increase from 8,005 in 2012 (see Table 
1).4 New cases (never previously treated) accounted for 40.9% 
of cases in 2012 and 38.6% in 2018. Previously treated cases 
accounted for 56.4% of cases in 2012 and 57.2% in 2018. 
In 2018, almost two-thirds (65.4%) of cases were treated in 
outpatient facilities (as in previous years), 13.5% of cases were 
treated in inpatient facilities, 10.5% in prisons, 8.6% in low-
threshold services, and 2% by general practitioners (see Table 2).
Main problem drug
Opioids (mainly heroin) were the main problem drug reported 
in 2018 and over the period. As a proportion of all cases 
treated, opioids decreased year-on-year from 52% in 2012 to 
42.3% in 2018 (see Table 3).
Cannabis remains the second most common main drug 
reported over the period. The proportion of cases treated 
decreased from 28.6% in 2012 to 23% in 2018.
Cocaine was the third most common main drug reported, 
accounting for 21.9% of cases in 2018. The number of cases 
treated for cocaine increased year-on-year from 2013 (708 
cases) to 2018 (2,254 cases), an increase of 218%. The most 
significant yearly increase in the number of cases presenting 
with cocaine as a main problem occurred between 2017 (1,500 
cases) and 2018 (2,254 cases), an increase of 50.3%.
In 2018, cannabis (38%) was the most common main problem 
drug reported by new entrants to treatment, followed by 
cocaine (31.1%) and opioids (18.1%) (see Table 3). Cocaine 
represented 31.1% of new cases in 2018, as compared with 9.1% 
in 2012. 
2012 2013 2014 2015 2016 2017 2018
n % n % n % n % n % n % n %
All cases 8005 9006 9890 9892 9227 8922 10 274
New cases 3272 40.9 3475 38.6 3776 38.2 3742 37.8 3526 38.2 3257 36.5 3962 38.6
Previously 
treated cases 4518 56.4 5239 58.2 5643 57.1 5855 59.2 5335 57.8 5242 58.8 5872 57.2
Treatment 
status 
unknown
215 2.7 292 3.2 471 4.8 295 3.0 366 4.0 423 4.7 440 4.3
Table 1: Number of cases treated for problem drug use, by treatment status, NDTRS 2012–2018
2012 2013 2014 2015 2016 2017 2018
n % n % n % n % n % n % n %
All cases 8005 9006 9890 9892 9227 8922 10 274
Outpatient 5299 66.2 5998 66.6 6251 63.2 5818 58.8 5481 59.4 5610 62.9 6715 65.4
Inpatient* 1124 14.0 1233 13.7 1348 13.6 1779 18.0 1885 20.4 1757 19.7 1384 13.5
Low threshold 711 8.9 812 9.0 1190 12.0 1197 12.1 886 9.6 792 8.9 887 8.6
Prison 642 8.0 747 8.3 844 8.5 827 8.4 737 8.0 651 7.3 1082 10.5
General 
practitioner 229 2.9 216 2.4 257 2.6 271 2.7 238 2.6 112 1.3 206 2.0
* Includes any service where the client stays overnight, e.g. inpatient detoxification, therapeutic communities, respite, and step-down.
Table 2: Number of cases treated for problem drug use, by type of service provider, NDTRS 2012–2018
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2012 2013 2014 2015 2016 2017 2018
n % n % n % n % n % n % n %
All cases 8005 9006 9890 9892 9227 8922 10 274
Opioids 4164 52.0 4625 51.4 4948 50.0 4732 47.8 4341 47.0 4016 45.0 4349 42.3
Cannabis 2290 28.6 2583 28.7 2730 27.6 2786 28.2 2439 26.4 2200 24.7 2358 23.0
Cocaine 666 8.3 708 7.9 853 8.6 1026 10.4 1138 12.3 1500 16.8 2254 21.9
Benzodiazepines 636 7.9 810 9.6 953 9.6 873 8.8 897 9.7 868 9.7 999 9.7
Z-drugs* 43 0.5 73 0.8 155 1.6 154 1.6 103 1.1 82 0.9 48 0.5
NPS 34 0.4 46 0.5 71 0.7 85 0.9 72 0.8 51 0.6 48 0.5
MDMA (ecstasy) 47 0.6 44 0.5 56 0.6 51 0.5 53 0.6 44 0.5 34 0.3
Amphetamines 50 0.6 54 0.6 58 0.6 63 0.6 55 0.6 40 0.4 57 0.6
Volatile inhalants 21 0.3 13 0.1 15 0.2 15 0.2 11 0.1 6 0.1 10 0.1
Other 54 0.7 50 0.6 51 0.5 107 1.1 118 1.3 115 1.3 117 1.1
New cases 3272 3475 3776 3742 3526 3257 3962
Cannabis 1499 45.8 1633 47.0 1696 44.9 1693 45.2 1452 41.2 1272 39.1 1505 38.0
Cocaine 297 9.1 320 9.2 425 11.3 513 13.7 568 16.1 748 23.0 1232 31.1
Opioids 1059 32.4 1034 29.8 1036 27.4 971 25.9 950 26.9 809 24.8 719 18.1
Benzodiazepines 279 8.5 345 9.9 419 11.1 340 9.1 353 10.0 290 8.9 345 8.7
Other 24 0.7 28 0.8 26 0.7 56 1.5 55 1.6 42 1.3 59 1.5
MDMA (ecstasy) 32 1.0 27 0.8 37 1.0 31 0.8 39 1.1 29 0.9 18 0.5
Z-drugs 19 0.6 22 0.6 58 1.5 46 1.2 41 1.2 22 0.7 17 0.4
NPS 20 0.6 25 0.7 43 1.1 53 1.4 36 1.0 21 0.6 25 0.6
Amphetamines 27 0.8 32 0.9 30 0.8 33 0.9 24 0.7 19 0.6 34 0.9
Volatile inhalants 16 0.5 9 0.3 6 0.2 6 0.2 8 0.2 ~ 0.2 8 0.2
* Z-drugs are non-benzodiazepine hypnotic sedative drugs, e.g. zolpidem and zopiclone.
NPS: New psychoactive substances.
~ Cells with five cases or less.
Table 3: Main problem drug (excluding alcohol) reported in 30 days prior to treatment, NDTRS 2012–2018
Drug treatment in Ireland  
2012–2018   continued
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Polydrug use
Over the period 2012–2018, six in 10 cases (59.5%) reported 
polydrug use (i.e. problem use of more than one drug). The 
proportion of cases with polydrug use decreased from 
61.5% in 2012 to 53.4% in 2018 (see Table 4). Alcohol (37.4%), 
benzodiazepines (36.2%), cannabis (35.3%), and cocaine (29.5%) 
were the most commonly reported additional drugs in 2018. 
Risk behaviour
The proportion of all cases that had ever injected decreased 
from 36% in 2012 to 26.7% in 2018 (a decrease of 142 cases over 
the period). Among new cases, the proportion that reported 
ever injecting decreased from 18% in 2012 to 7.9% in 2018. The 
proportion of all cases currently injecting (i.e. in the 30 days 
prior to treatment) decreased from 35.6% in 2012 to 29.7% in 
2018.
Sociodemographic characteristics
The following sociodemographic characteristics of the cases 
were noted:
• Seven in every 10 cases reported over the period were 
male.
• The median age of cases when entering treatment 
increased from 28 years in 2012 to 31 years in 2018.
• Under 18s accounted for 8.4% of cases in 2012 and 7.1% in 
2018.
• Cases recorded as homeless increased in proportion, from 
5.8% in 2012 to 9.5% in 2018.
• The proportion of cases with an Irish Traveller ethnicity was 
2.8% in 2012 and 3.3% in 2018.
• A large proportion of cases (61.9%) were unemployed in 
2018, as in previous years.
• The proportion of cases in paid employment increased 
from 7.2% in 2012 to 16.9% in 2018.
Sociodemographic characteristics of cases – 
cocaine as main problem
The following sociodemographic characteristics of cases with 
cocaine as a main problem were noted:
• Eight in 10 cases reported over the period were male.
• The proportion of female cases increased from 18% in 2012 
to 20.1% in 2018.
• The median age of cases when entering treatment 
increased from 29 years in 2012 to 30 years in 2018.
• Under 18s accounted for 1.4% of cocaine cases in 2012 and 
1.7% in 2018.
• The proportion of cases in paid employment increased 
from 15.8% in 2012 to 35% in 2018.
• Cases with polydrug use decreased in proportion, from 
76.6% in 2012 to 56.1% in 2018.
• In 2018, the most common additional substances were 
alcohol (56%), cannabis (47.8%), and benzodiazepines 
(23.8%).
2012 2013 2014 2015 2016 2017 2018
n % n % n % n % n % n % n %
All cases 8005 9006 9890 9892 9227 8922 10 274
One drug only 3083 38.5 3340 37.1 3993 40.4 3872 39.1 3524 38.2 3816 42.8 4787 46.6
Two or more 
drugs 4922 61.5 5666 62.9 5897 59.6 6020 60.9 5703 61.8 5106 57.2 5487 53.4
Table 4: Polydrug use in cases treated for problem drug use, NDTRS 2012–2018
Cathy Kelleher
1 The NDTRS is the national epidemiological surveillance system 
that reports on treated problem drug and alcohol use in Ireland. 
Established in 1990, the NDTRS is maintained by the National 
Health Information Systems (NHIS) of the Health Research Board 
(HRB) on behalf of the Department of Health.
2 Health Research Board (2019) National Drug Treatment Reporting 
System 2012–2018 drug data. Dublin: Health Research Board. 
Available online at: http://www.drugsandalcohol.ie/30969 and at  
http://www.hrb.ie/publications. Alcohol figures are published in a 
separate bulletin.
3 The data reflect the number of entries into treatment in a 
calendar year, rather than the number of persons treated in that 
year.
4 The number of services participating in the NDTRS varies annually, 
making small fluctuations in the numbers of cases difficult to 
interpret. Overall, coverage of services was 69.5% for 2018.
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alcohol treatment 
data for 2004–2018 
available online
Drug and alcohol treatment data for 2004–2018 from the National 
Drug Treatment Reporting System (NDTRS) are now available online 
through the Health Research Board (HRB) National Drugs Library 
website at http://www.drugsandalcohol.ie/tables/. The 
NDTRS is a health information system that collects anonymous 
information about drug and alcohol treatment episodes in 
Ireland.
The online database contains 14 years of treatment data 
that can be searched using interactive tables to produce 
customised reports. Variables available for analysis include year, 
age, treatment status, gender, geographical region of residence 
(county, Health Service Executive (HSE) region, local health 
office, local or regional drug and alcohol task force area).
The interactive tables now enable the grouping of results 
by primary categories and secondary categories based on 
variables such as source of referral, employment status, living 
status, type of accommodation, education, polysubstance use, 
and injecting.
When interpreting the data, it should be noted that each NDTRS 
record relates to a treatment episode (a case) and not to a 
person. As there is currently no unique health identifier system 
in place in Ireland, the same person can be counted more than 
once in a reporting year if they had more than one treatment 
episode in that year.
Before using the interactive tables, you will be asked to read 
and accept some terms and conditions. These include an 
undertaking not to publish tables where any individual cell 
contains less than five cases; to acknowledge the NDTRS as the 
source of data, and to provide the HRB National Drugs Library1 
with copies of all documents in which NDTRS data are used.
Cathy Kelleher
1 For further information on the interactive tables, email: 
drugslibrary@hrb.ie
Alcohol and drug use 
among young people 
and adolescents 
in Ireland – results 
from My World and 
Growing Up in Ireland 
surveys
Two recent surveys provide an insight into alcohol and drug use 
among young people in Ireland. My World Survey 2 (MWS-2),1 
developed by University College Dublin (UCD) and Jigsaw, the 
National Centre for Youth Mental Health, is a comprehensive 
study of young people’s mental health and wellbeing and a 
follow-up to the 2012 My World Survey 1 (MWS-1).2
The survey population for MWS-2 was 19,407 and consisted 
of 10,459 adolescents (aged 12–19 years) from 83 secondary 
schools and 8,290 young adults aged 18–25 years in third-
level education or employment. Seldom-heard young adults 
included 314 young people in Youthreach, 292 young people in 
Colleges of Further Education (CFE)/community training, and 
52 young people with physical disabilities. Of the adolescent 
participants, 56% were female, as were 69% of the young adult 
participants.
Since 2006, the Growing Up in Ireland (GUI) survey, a national 
longitudinal study of children and young people, has followed a 
cohort of children born in 1998. Four waves of interviews have 
been conducted with this cohort, when they were aged 9, 13, 
17–18, and 20 years old. The most recent report presents the 
findings of 5,191 interviews of the 20-year-olds, which were 
conducted in 2018 and 2019.3
My World Survey results
The AUDIT (Alcohol Use Disorders Identification Tool),4 a 10-
item tool used to screen for harmful and hazardous drinking, 
was used to classify young people into one of four categories 
of drinkers: low risk; problem drinking; harmful and hazardous 
drinking; and possible alcohol dependence. Drug use was 
assessed with the Drug Abuse Screen Test (DAST), a 10-item 
self-report instrument that assesses drug use in the past 12 
months.
Key findings
Adolescents
• 57% of adolescents had never drank alcohol, compared 
with 49% of adolescents in MWS-1.
• The adolescents who did drink alcohol reported engaging in 
more problematic drinking than adolescents in MWS-1 (see 
Figure 1).
• Similar to MWS-1, problematic alcohol use was significantly 
associated with more severe feelings of anxiety and 
depression among adolescents.
• Of note, adolescents who reported having made a suicide 
attempt presented with significantly higher levels of 
problematic drinking and were also more likely to have 
smoked cannabis.
• 15% (18% males vs 13% females) reported that they had 
smoked cannabis.
• The reported use of cannabis in first year of secondary 
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school was 3%; this increased to 27% in fifth year and 36% 
in sixth year.
• Of those who reported having smoked cannabis, 43% 
reported that they were aged 15 years or younger when 
they first tried cannabis.
Young adults
• Some 10% of young adults reported having never drank 
alcohol, compared with 7% in MWS-1.
• Of the young adults who reported drinking, 47% were in 
the low-risk drinking range, 39% were classified as problem 
drinkers, 8% as harmful and hazardous drinkers, and 6% as 
having possible alcohol dependence.
• Young males were less likely to be in the low-risk drinking 
range (45% vs 50% females) and more likely to be in the 
hazardous range (9% vs 6%) and the possible alcohol 
dependence range (8% vs 6%).
• The proportion of problem drinkers in the problematic, 
hazardous, and possible alcohol dependence categories 
was significantly lower among young adults in MWS-2 
compared with MWS-1.
• Similarly to MWS-1, the findings from MWS-2 also 
demonstrated a significant association between 
problematic alcohol use and depression and anxiety.
• Problematic drinking patterns were also significantly 
associated with lower levels of family support, but not 
friend support, among young adults.
• Young adults who made a suicide attempt were more likely 
to be in the possible alcohol dependence category, while 
young males who reported a suicide attempt were more 
likely to be in the hazardous or harmful drinking category 
and were more likely to be in the moderate/substantial/
severe categories for drug abuse.
• 53% of young adults (59% males vs 50% females) reported 
that they had smoked cannabis in their lifetime. Of those 
who reported ever smoking cannabis, 83% reported first 
trying cannabis between 15 and 19 years.
• 40% reported that they had used drugs other than those 
required for medical reasons.
• According to the DAST cut-off points, 49% of young adults 
presented with no drug problems, 37% fell into the low level, 
10% were in the moderate level, 2% were in the substantial 
level, and 1% were in the severe level for drug problems.
• Problematic drug use was significantly associated with 
severe depression and very severe anxiety.
Seldom-heard group
• There was no significant difference between Youthreach 
and the young adult or adolescent sample in terms of 
alcohol behaviour, with 46% in the low-risk drinking range, 
39% in the problem drinking range, 11% in the harmful and 
hazardous drinking range, and 5% in the possible alcohol 
dependence range.
• Similarly, there was no significant difference between the 
CFE/community training group and the young adult or 
adolescent sample in terms of alcohol behaviour, with 47% 
in the low-risk drinking range, 32% in the problem drinking 
range, 11% in the harmful and hazardous drinking range, and 
10% in the possible alcohol dependence range.
• There was no significant difference in alcohol behaviour 
between young people with a physical disability and the 
young adult or adolescent samples, with 57% in the low-risk 
drinking range, 21% in the problematic drinking range, 14% 
in the harmful and hazardous drinking range, and 7% in the 
possible alcohol dependence range.
• Associations between alcohol behaviour and mental health 
or substance use were not reported for the seldom-heard 
group.
• 45% of young people in Youthreach reported having used 
drugs, other than those required for medical reasons, 
My World and Growing  
Up in Ireland surveys  continued
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Figure 1: Alcohol behaviour by wave, in those who reported to have drank alcohol
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and 66% reported having smoked cannabis, which was 
significantly higher than the young adult or adolescent 
sample.
• Those in the CFE/community training group and those with 
a physical disability were less likely to report having used 
drugs, other than those required for medical reasons, than 
the young adult or adolescent sample.
Growing Up in Ireland results
The GUI reports on the frequency of alcohol use and the age 
of first use. It also contains a number of questions on cannabis 
and other drugs.
Key findings 
• 96% of 20-year-olds reported that they had ever 
consumed alcohol, while 93% reported that they currently 
drank alcohol.
• On average, respondents were 15.9 years old when they had 
their first alcoholic drink.
• One-quarter (24%) consumed alcohol at least twice weekly.
• At the age of 13 years, just 15% of the sample had ever 
consumed alcohol, but that figure increased to 89% by the 
age of 17/18 years.
• 59% of all 20-year-olds reported that they had tried 
cannabis: 26% said they had tried cannabis once or twice, 
18% took it occasionally, 6% took it more than once a week, 
and 9% did not take cannabis anymore.
• The percentage who ever tried cannabis increased 
markedly as the young people moved through their teens: 
1% had tried cannabis by age 13; 30% had tried it by age 
17/18; and 59% had tried it by age 20.
• In relation to other illicit drug use (e.g. ecstasy and cocaine), 
13% reported that they had tried them less than five times, 
while 15% said they had done so five or more times.
• 9% had used prescription drugs for recreational use.
Conclusions
In terms of alcohol use, the findings indicate that more young 
people are abstaining from alcohol. However, for adolescents 
who do drink, they engaged in riskier alcohol behaviour than 
previously reported. Most young people had engaged in at least 
one occasion of illicit drug use in their lifetime. Six in 10 young 
people had tried cannabis at least once, with a considerable 
minority engaging in occasional or weekly use. Almost three 
in 10 young adults reported having tried other illicit drugs 
such as cocaine and ecstasy. Significant associations were 
found between alcohol and illicit drug use and anxiety and 
depression, indicating a relationship between substance use 
and poorer mental wellbeing among young people in Ireland. 
Alcohol use was also strongly associated with illicit drug use, 
indicating evidence for polydrug use among young people.
Claire O’Dwyer and Deirdre Mongan
1 Dooley B, O’Connor C, Fitzgerald A and O’Reilly A (2019) My World 
Survey 2: the national study of youth mental health in Ireland. 
Dublin: UCD and Jigsaw. https://www.drugsandalcohol.ie/31343/
2 Dooley B and Fitzgerald A (2012) My World Survey: national study 
of youth mental health in Ireland. Dublin: Headstrong, National 
Centre for Youth Mental Health / UCD School of Psychology. 
https://www.drugsandalcohol.ie/17589/
3 Economic and Social Research Institute (ESRI) and Trinity College 
Dublin (TCD) (2019) Growing Up in Ireland. Wave 4 at 20-years. 
Dublin: ESRI, TCD and Department of Children and Youth Affairs. 
https://www.drugsandalcohol.ie/31381/
4 Saunders JB, Aasland OG, Babor TF, de La Fuente JR and Grant 
M (1993) Development of the Alcohol Use Disorders Identification 
Test (AUDIT): WHO Collaborative Project on Early Detection of 
Persons with Harmful Alcohol Consumption-II. Addiction, 88(6): 
791–804.
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Alcohol treatment 
figures from the 
NDTRS, 2012–2018
The National Drug Treatment Reporting System (NDTRS) is 
a national surveillance database on treatment for problem 
drug and alcohol use in Ireland. In November 2019, the NDTRS 
published its latest alcohol treatment figures, which cover the 
seven-year period 2012–2018. Over this period, 54,263 cases 
were treated for alcohol as a main problem.1
Key findings
The number of cases decreased to 7,464 in 2018 from a high 
of 8,609 in 2012. In 2018, there was a small increase in cases, 
from 7,350 in 2017. The proportion of new cases treated (those 
never before treated for problem alcohol use) decreased from 
48.2% in 2012 to 43.3% in 2018 (see Table 1). The proportion of 
previously treated cases decreased slightly over the reporting 
period from 50.6% in 2012 to 49.6% in 2018.
It is important to note that each case in the NDTRS database 
relates to a treatment episode and not to a person. This 
means that the same person may be counted more than once 
in the same calendar year, if that person had more than one 
treatment episode in that year.
Case characteristics
In 2018, as in previous years, over one-half (54.8%) of cases 
were treated in outpatient facilities (see Table 2). In addition, 
almost 4 in 10 cases (37.4%) were treated in residential settings, 
again similar to previous years.
The 2018 data show that the median age to start drinking for 
cases in treatment for problem alcohol use was 15 years, a 
trend that has remained steady over the seven-year reporting 
period. Over this period, the proportion of cases classified 
as dependent increased from 55.7% in 2012 to 71% in 2018. 
Dependent means that a person feels that they are unable 
to function without alcohol and the consumption of alcohol 
becomes an important – or sometimes the most important – 
factor in their life.2 A significant finding of the analysis was that 
in 2018 approximately two-thirds (65.6%) of new cases were 
classified as alcohol-dependent.
The median age of treated cases increased over the seven-year 
period from 40 years in 2012 to 41 years in 2018. The median 
age of new cases also continued to rise from 37 years in 2012 to 
39 years in 2018.
In 2018, over one-half (50.7%) of cases were unemployed, 
while the proportion of cases recorded as homeless increased 
from 5.6% in 2012 to 9.6% in 2018. Also, in 2018, 1.9% of cases 
identified as Irish Traveller.3
One in five cases treated for problem alcohol use (21.5%) 
reported problem use of more than one substance (polydrug 
use) in 2018. Cannabis (58.6%) was the most common additional 
drug reported in 2018, followed by cocaine (48.2%) and then 
benzodiazepines (23.4%). Cocaine increased from 28.1% in 2012 
to 48.2% in 2018.
Case gender, 2018
The majority of cases in 2018 were male (64.5%), similar to 
previous years. The median age of treated cases for females 
(43 years) is higher than for males (40 years). This is further 
reflected in the median age for new cases entering treatment 
(males 39 years vs females 42 years). Females also account for 
a higher proportion of cases in treatment aged 50 years or over 
2012 2013 2014 2015 2016 2017 2018
n % n % n % n % n % n % n %
All cases 8609 7819 7760 7618 7643 7350 7464
New cases 4149 48.2 3708 47.4 3772 48.6 3553 46.6 3678 48.1 3500 47.6 3230 43.3
Previously 
treated cases 4353 50.6 3932 50.3 3807 49.1 3948 51.8 3783 49.5 3652 49.7 3705 49.6
Treatment 
status 
unknown
107 1.2 179 2.3 181 2.3 117 1.5 182 2.4 198 2.7 529 7.1
2012 2013 2014 2015 2016 2017 2018
n % n % n % n % n % n % n %
All cases 8609 7819 7760 7618 7643 7350 7464
Outpatient 4510 52.4 4221 54.0 4133 53.3 4018 52.7 4005 52.4 3894 53.0 4087 54.8
Inpatient* 3309 38.4 2809 35.9 2803 36.1 2916 38.3 2994 39.2 2949 40.1 2792 37.4
Low threshold 519 6.0 521 6.7 605 7.8 480 6.3 495 6.5 436 5.9 451 6.0
Prison 271 3.1 268 3.4 219 2.8 204 2.7 149 1.9 71 1.0 134 1.8
* Includes any service where the client stays overnight, e.g. inpatient detoxification, therapeutic communities, respite, and step-down.
Table 2: Number of cases in treatment with alcohol as a main problem, by type of service provider, NDTRS 2012–2018
Table 1: Number of cases with alcohol as a main problem, by treatment status, NDTRS 2012–2018
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(30.6%) than males aged 50 years or over (25.1%). Homelessness 
was more prevalent among males (11.6%) than females (5.8%).
In 2018, 73.4% of males were classified as alcohol-dependent, 
as compared with 66.8% of females.
The proportion of cases with an additional other problem 
drug was higher for males (24.1%) than for females (16.7%). 
The four most common additional drugs (cannabis, cocaine, 
benzodiazepines, and opioids) for cases in alcohol treatment 
are the same for both males and females. There are, however, 
differences in the proportion reporting use of these drugs 
based on gender.
Conclusion
The findings of this bulletin can be used to inform research, 
policy, and practice in the area of alcohol addiction and 
treatment in Ireland.
Ita Condron 
1 Health Research Board (2019) National Drug Treatment Reporting 
System 2012–2018 alcohol data. Dublin: Health Research Board. 
https://www.drugsandalcohol.ie/30970
2 Health Service Executive (2019) Alcohol dependence. For further 
information, visit: https://www2.hse.ie/wellbeing/alcohol/
dependence/signs-and-patterns.html
3 Based on the 2016 Census, the proportion of Irish Travellers 
in the general population is 0.7% (Central Statistics Office, 
2019). For further information, visit: https://www.cso.ie/en/
releasesandpublications/ep/p-cp8iter/p8iter/p8e/
Repeated cross-
sectional study of 
factors associated 
with pregabalin-
positive poisoning 
deaths in Ireland
Introduction
Pregabalin is a prescribed medication licensed in Europe 
for use in the treatment of epilepsy, neuropathic pain, and 
generalised anxiety disorder.1 However, the pharmacokinetic 
properties of pregabalin, which include its rapid absorption, 
fast onset of its relaxant and sedative effects, and its reduced 
withdrawal symptoms, can lead to the potential risk of misuse. 
As outlined in a previous Drugnet Ireland article,2 in Ireland, the 
rates of prescribing pregabalin have increased in line with an 
increase in poisoning deaths, where pregabalin was present on 
toxicology.
The increasing use of pregabalin and its presence in poisoning 
deaths, particularly with opioids, highlight it as a potential drug 
of abuse. Misuse of pregabalin has been reported, especially 
among people with a history of opioid misuse,3,4 people in 
opioid substitution treatment,5 and people in prisons.6 A recent 
Irish study, using data from the National Drug-Related Deaths 
Index (NDRDI), examined factors associated with pregabalin-
positive poisoning deaths (PPPD) between 2013 and 2016.7
Methods
Data for this study were extracted from the NDRDI. The NDRDI’s 
definition of a poisoning death is a death directly due to the 
toxic effect of one or more substances on the body. For this 
study, PPPD included all poisoning deaths where pregabalin was 
present on the toxicology report, with years of death 2013–2016 
inclusive as the observation period. Analysis included univariate 
and multivariate logistic regression to estimate unadjusted and 
adjusted odds ratios (OR) and 95% confidence intervals (CI) 
for factors associated with PPPD (primary outcome) by logistic 
regression models for the total sample and stratified by gender.
Results
Pregabalin
Pregabalin was present on 240 (16%) toxicology reports of 1,489 
poisoning deaths, significantly rising from 18 (5%) in 2013 to 
94 (27%) in 2016. While the total number of poisoning deaths 
appeared to decrease over the reporting period, there was an 
increase in PPPD (see Table 1). Women, opioid misuse, being in 
receipt of treatment for problem drug use, and year of death 
(2016 vs 2013) were associated with increased odds of PPPD. 
Alcohol dependence was associated with reduced odds of 
PPPD. Analysis was then stratified by gender. For men, opioid 
misuse, being in receipt of treatment for problem drug use, and 
year of death were associated with increased odds of PPPD, 
while alcohol dependence was associated with reduced odds 
of PPPD. For women, being in receipt of treatment for problem 
drug use and year of death were associated with increased 
odds of PPPD.
Polydrugs
Polydrugs were present on the toxicology reports of all PPPD 
(n=240). Almost all (234, 97.5%) had a positive toxicology report 
for other central nervous system (CNS) depressant drugs, 
mainly opioids (211, 88%), followed by benzodiazepines (207, 
86%) and alcohol (58, 24%). Methadone (122, 51%) was the main 
opioid reported in PPPD, followed by heroin (44, 18%). The odds 
of opioid drugs being present on toxicology reports (versus 
none) were 6.54 times more likely for PPPD than pregabalin-
negative poisoning deaths (PNPD), with the odds for women 
twice that for men.
Two or more other CNS depressant drugs were present in the 
majority (205, 85%) of PPPD toxicology reports. The odds of 
two or more CNS depressant drugs being present on toxicology 
reports (versus none) were 10.38 times more likely for PPPD 
compared with PNPD, with the odds for women three times 
that for men. This is significant as pregabalin can exacerbate 
the side-effects of CNS depressant drugs, and with multiple 
CNS depressant drugs present in PPPD, the synergistic effect of 
the combination of these drugs increases the risk of death.
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Pregabalin-positive poisoning 
deaths in Ireland   continued
The odds of antidepressant drugs present on toxicology (versus 
none) were 5.49 times more likely for PPPD than PNPD; for 
antipsychotic drugs, the odds ratio was 3.82; and for Z-drugs 
it was 2.74. The presence of cocaine on toxicology reports was 
not statistically significantly associated with PPPD.
Conclusions
The authors conclude that the study findings suggest the 
inappropriate use of pregabalin among those who are 
known to misuse opioids and those in receipt of treatment 
for problematic drug use. More guidance and training 
for prescribers and treatment providers as well as the 
development of policies, including consideration given to 
scheduling pregabalin as a controlled drug, is recommended 
to better inform the public and medical practitioners of 
the potential harm due to ‘off label’ prescribing and of 
inappropriate use of pregabalin.
Close monitoring of prescribing practices, diversion, and 
misuse of pregabalin, especially among those who use opioids 
and within the treatment setting in Ireland, is urgently required. 
Any treatment with pregabalin should be subject to regular 
review with caution adhered to when considering prescribing 
pregabalin to women who are taking other drugs, especially 
CNS depressants. In Ireland, the nationwide implementation of 
an ePrescription system would assist in this process. In addition, 
an ePrescription system would help prevent people altering 
prescriptions or receiving multiple private prescriptions from 
different medical practitioners.
Ena Lynn
1 European Medicines Agency (2019) Pregabalin: summary of 
product characteristics. Amsterdam: European Medicines Agency. 
Available online at: http://web.archive.org/web/20190613071438/
https://www.ema.europa.eu/en/documents/product-
information/lyrica-epar-product-information_en.pdf
2 Lynn E (2019) Has an increase in the dispensing of pregabalin 
influenced poisoning deaths in Ireland? Drugnet Ireland, 71: 15–17. 
https://www.drugsandalcohol.ie/31455/
3 Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, et al. (2017) 
Risk to heroin users of polydrug use of pregabalin or gabapentin. 
Addiction, 112(9): 1580–89.
4 United Nations Office on Drugs and Crime (2019) World drug 
report 2019. Booklet 3: Depressants. Vienna: United Nations Office 
on Drugs and Crime. https://www.drugsandalcohol.ie/30717/ 
5 McNamara S, Stokes S, Kilduff R and Shine A (2015) Pregabalin 
abuse amongst opioid substitution treatment patients. Ir Med J, 
All poisoning deaths Men Women
Unadjusted model Adjusted model Adjusted model Adjusted model
Factors (reference 
category)
PNPD PPPD Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Gender
Women 356 111 (24%) 2.16 (1.63–2.86)*** 2.69 (1.95–3.70)***
Men(ref) 893 129 (13%) 1.00 1.00
Year of death
2013(ref) 382 18 (5%) 1.00 1.00 1.00 1.00
2014 382 53 (14%) 3.33 (2.04–6.18)*** 3.62 (2.04–6.42)*** 4.46 (2.00–10.05)*** 2.74 (1.18–6.34)*
2015 290 75 (21%) 5.49 (3.21–9.39)*** 5.55 (3.20–9.66)*** 5.14 (2.28–11.56)*** 6.05 (2.76–13.26)***
2016 260 94 (27%) 7.67 (4.52–13.01)*** 7.95 (4.58–13.79)*** 11.01 (5.02–24.14)*** 5.24 (2.35–11.69)***
History of alcohol dependency
Yes 360 48 (12%) 0.62 (0.44–0.87)** 0.59 (0.41–0.85)** 0.45 (0.27–0.76)** 0.84 (0.48–1.47)
No(ref) 889 192 (18%) 1.00 1.00 1.00 1.00
History of opioid misuse
Yes 553 160 (22%) 2.52 (1.88–3.37)*** 1.74 (1.17–2.59)** 1.83 (1.09–3.08)* 1.56 (0.81–3.01)
No(ref) 696 80 (10%) 1.00 1.00 1.00 1.00
In receipt of treatment for problematic drug use
Yes 197 89 (31%) 3.15 (2.32–4.26)*** 1.95 (1.33–2.86)** 1.80 (1.10–2.95)* 2.57 (1.31–5.01)**
No(ref) 1052 151 (13%) 1.00 1.00 1.00 1.00
Adjusted model is for all predictors identified as significant in the unadjusted models. Variables significant at *** p<0.001; ** p<0.01; * p<0.05.
Table 1: Factors significantly associated with PPPD, 2013–2016 (n=1489)
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108(10): 309–310. https://www.drugsandalcohol.ie/24965/
6 Farmer D (2013) The prescribing and management of gabapentin 
and pregabalin in HM Prisons and Immigration Removal Centres 
in England: Collaborative audit report. NHS East & South 
East England Specialist Pharmacy Services. Available online 
at: https://www.sps.nhs.uk/wp-content/uploads/2013/07/
Gabapentin20and20Pregabalin20Offender20Health      
20Audit20Report.pdf
7 Lynn E, Cousins G, Lyons S and Bennett K (2020) A repeated   
cross-sectional study of factors associated with pregabalin-
positive poisoning deaths in Ireland. Drug Alcohol Depend, 206: 
107741. https://www.drugsandalcohol.ie/31323/ 
EU drug markets 
report, 2019
On 26 November 2019, the EU drug markets report was 
published by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) and the European Union Agency 
for Law Enforcement Cooperation (Europol).1 This is the third 
comprehensive overview of illicit drug markets in the European 
Union (EU) and, while building on reports published in 2013 and 
2016, it provides greater insight and a ‘richer picture’ (p. 7) of 
the current state of drug markets in the EU.2,3
Utilising a broad definition of the illicit drug market, including 
illicit drug production, trafficking, and wholesale and retail 
distribution to the end user, the current report focuses on 
three areas. First, it examines the impact of drug markets and 
what drives their development. Second, it provides an outline 
of the main drug types in illicit drug markets. Third, it describes 
how EU member states respond to the different components 
of the illicit drug markets at a European and national level via 
policy, legislation, and operational responses.
Impacts and drivers of drug markets
The main source of income for organised crime groups (OCGs) 
is believed to come from the illicit drug market. Data for 2017 
have indicated that it is valued at €30 billion. Figure 1 shows a 
breakdown of the estimated retail value of the main drugs in 
the EU. 
The impact of the drug market is broad, not only affecting 
individuals who use drugs but also affecting society as a whole. 
It has also been shown to be connected to wider criminal 
activities of OCGs and terrorism; has impacted on the legal 
economy; has resulted in increased violence, intimidation, 
corruption, human trafficking, and migrant smuggling; and has 
harmed the environment and weakened governance.
€30 billion
EU retail market size 
minimum estimate
Cannabis
39%
How to read the chart
Central estimate
Estimated range €0.3 bn  €0.8 bn  
€0.5 bn 
3%
2%
€11.6 bn 
€12.8 bn 
€10.5 bn 
€0.5 bn €1.0 bn 
€9.1 bn 
€7.4 bn 
€6.4 bn 
€7.6 bn 
€9.1 bn 
€10.5 bn 
Cocaine
31%
Heroin
25%
EU retail market size 
minimum estimate
(% of total)
Amphetamines  Ecstasy/MDMA
Source: EU drug markets report, 2019, Figure 1.1, p. 29
Figure 1: Estimated retail value of the illicit market for the main drugs in the EU
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Main drug markets in the EU
The availability of high-purity, high-potency products at cheap 
prices continues to be widespread in the EU. The report has 
provided valuable insight into recent developments from 
production to distribution of the main drugs, such as cannabis, 
heroin, cocaine, amphetamines, MDMA and methamphetamine, 
and new psychoactive substances. Advancements in technology 
and digitalisation along with awareness of gaps in drug 
regulations and control have been exploited by OCGs, enabling 
them to take advantage of a more global international market. 
Traditionally, OCGs have utilised several approaches to move 
and distribute products quickly across borders, for example, 
large-volume shipments and postal services. However, the 
sale of drugs occurs increasingly online via the surface web 
and darknet markets as well as via social media and apps. This 
approach removes the need for a traditional infrastructure, 
making it easier for actors to get involved in the illicit drug 
market. Nevertheless, it does create more difficulties for 
policing and public health.
Responding to drug markets
In order to respond to the challenges identified in the report, 
several areas need to be addressed. Table 1 identifies the key 
themes and implications for action. 
Key themes Threat Action needed
Strengthening efforts to 
target top-level OCGs 
active in the global drug 
market 
• Evolving OCG business model
• Ability to exploit new 
opportunities
• Increased investment to strengthen information-sharing, 
analysis, and cooperation at operational, strategic, and 
policy levels
Reducing vulnerabilities at 
external borders
• Wholesale trafficking of drugs 
through key entry points into 
the EU
• Investment in risk analysis, profiling, and intelligence-
sharing
• Implementation of proven approaches to make external 
EU borders stronger
• Multiagency cooperation within and across EU borders 
essential
Focusing on key 
geographical locations for 
trafficking and production
• Areas that have increased 
drug market activities
• Targeting of areas with special measures
• Strategic priority to remain vigilant for displacement 
activities
Investing in forensic and 
toxicological capacity
• Growing importance of highly 
potent synthetic substances
• Introduction of new 
psychoactive substances and 
precursor
• Investment at EU and member state level to overcome 
limited capacity that is preventing development of 
effective policy and action
Addressing the links with 
other important security 
threats
• Links to human trafficking
• Links to terrorism
• Further study of links
• Strengthening of multiagency partnerships to increase 
action in areas of prevention and prosecution of 
perpetrators as well as victim protection
Recognising the costs of 
drug-related violence and 
corruption
• Drug-related violence and 
corruption within the EU
• Concerted actions across several policy areas
Responding to digitally 
enabled drug markets
• New technologies • Threat analysis
• Specialist skills, e.g. forensic science, financial 
investigations, information and communications 
technology
Acting at a global level • Globalised drug market • Engagement with international organisations and third 
countries crucial
• Understanding of developments in drug production and 
trafficking in non-EU countries
• Collaboration with countries neighbouring the EU or on 
main trafficking routes to EU essential, particularly where 
OCGs have links to ethnically based groups residing in 
the EU
Source: Adapted from EU drug markets report, 2019, pp. 14–15
Table 1: Key themes and implications for action in responding to drug market challenges
EU drug markets report, 2019   
continued
20
dr
ug
ne
t I
RE
LA
ND
   
   
Iss
ue
 7
2 
 |  
 W
in
te
r 2
02
0 EU drug markets report, 2019   
continued
Policies and actions
Due to the complexity and the adaptability of the ever-evolving 
illicit drug markets in the EU, policies and responses from 
member states have been essential in order to target existing 
and imminent challenges that have arisen and continue to 
arise. Responses have included operational activities, the 
implementation of strategies and legislation, and bilateral 
arrangements. While targeting serious OCGs involved in the 
drug trade is deemed a high priority, the report points out 
that the impact of the drug market is both direct (e.g. health 
and security) and indirect (e.g. violence, safety, environment). 
This has negative connotations across different policy areas. 
These links need to be examined further to order to inform and 
integrate stronger responses to the illicit drug market.
Conclusion
The report provides a comprehensive overview of the EU illicit 
drug markets and their continuing development. It highlights 
that the impact of the illicit drug markets on individuals and 
society is extensive and wide-ranging. Reducing the harms 
linked with the drug markets must continue to be prioritised. 
The implementation of policy across domains at both EU 
and member state level is considered the most adept way to 
achieve this outcome. This aligns with the EU’s commitment to 
avail of a stable and evidence-based approach in response to 
existing challenges in this field.
Ciara H Guiney
1 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and Europol (2019) EU drug markets report 2019. 
Luxembourg: Publications Office of the European Union. https://
www.drugsandalcohol.ie/31354/
2 EMCDDA and Europol (2016) EU drug markets report 2016: in-
depth analysis. Luxembourg: Publications Office of the European 
Union. https://www.drugsandalcohol.ie/25357/
3 EMCDDA and Europol (2013) EU drug markets report: a strategic 
analysis. Luxembourg: Publications Office of the European Union. 
https://www.drugsandalcohol.ie/19227/
An Garda Síochána 
Policing Plan, 2019
An Garda Síochána (AGS) Policing Plan 2019 identifies the 
main policing concerns for 2019.1 It is the first of three plans 
proposed by the new Garda Commissioner, Drew Harris, that 
will implement the new AGS Strategy Statement, 2019–2021 
through numerous initiatives, which will gradually assist AGS 
to reach its strategic outcomes.2 The AGS mission for the 
duration of the strategy is simply ‘keeping people safe’ (p. 1).2 
Progress through this strategy will be achieved incrementally 
by implementing various initiatives through the policing plans 
annually. Six areas were highlighted by AGS in 2019: community 
policing; protecting people; a secure Ireland; a human 
rights foundation; our people – our greatest resource; and 
transforming our service.1,2 Initiatives related to these areas are 
highlighted below.
Community policing
The Policing Plan 2019 seeks to introduce a new community 
policing framework in four Garda divisions in 2019. The 
locations of the first five divisions to implement this framework 
were announced on 10 October 2019; these cover Galway, Cork 
City, Dublin South Central, Meath/Westmeath, and Limerick. 
AGS also intends to interact and collaborate with communities 
and stakeholders to determine what their policing needs are 
and how to achieve them.
Protecting people
AGS aims to provide protection from crime and ensure 
safety on Irish roads by building AGS capacity to oversee and 
coordinate how it responds to crime. The intention is to build 
crime prevention capacity to reduce crime and the fear of 
crime. In addition, AGS aims to target organised crime groups 
that hurt communities through violence and the sale or 
supply of drugs. Moreover, it plans to improve the investigative 
response to crime by implementing the Investigation 
Management System and other information and communication 
technologies.
A secure Ireland
The objective here is to improve security capabilities by 
implementing recommendations put forward in A policing 
service for the future.3 For example, AGS intends to carry 
out intelligence-led operations nationally and internationally 
to address terrorism. Gardaí will receive specialised training 
in accordance with international best practice to help them 
locate and seize finances used for the purpose of terrorism.
Human rights foundation
The Policing Plan 2019 seeks to build a policing infrastructure 
that is centred on human rights. AGS aims to embed human 
rights and ethical behaviour into how Gardaí police and 
specifically deal with criminal justice service users who are 
vulnerable.
Our people – our greatest resource
People are viewed as AGS’s greatest resource. AGS aims to 
increase engagement and support and provide opportunities 
for continuous development. The new People Strategy 2019–
2021 will be implemented and will help determine whether 
Gardaí are in the role most suited to them, in the right place, 
and at the right time.4 In addition, it is intended to establish 
a learning culture and to increase leadership capacity via 
leadership training. Excellent performance will be encouraged 
and acknowledged. Underperformance and unethical 
behaviour will be targeted. To support health and wellness, AGS 
will invest in employees’ wellbeing.
Transforming our service
The Policing Plan 2019 aims to implement a new operational 
model. The aim is to provide a more effective service, build 
public confidence via greater accountability and transparency, 
and improve communication both internally and externally. In 
addition, AGS plans to re-establish confidence in crime data 
by working with the Central Statistics Office and by ensuring 
greater accuracy and governance.
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Policing Plan, 2019   continued
Although drugs are only mentioned by name in the 
‘protecting people’ section, it is implied throughout the plan.1 
Responsibility for actioning and reporting on the progress of 
each initiative in the plan has been assigned to an Assistant 
Commissioner or Executive Director, who will then report to 
the Garda Commissioner and the Policing Authority once a 
month. Moreover, key performance indicators will be used 
to statistically determine that improvement has occurred 
in several areas, such as public perception, public safety 
and demand, offender accountability, roads policing, victim 
engagement, and data quality.1
The Garda Commissioner believes that this plan is ‘ambitious’ 
but he is ‘committed to delivering a victim centred policing 
service, focussed on keeping people safe, protecting the 
most vulnerable and providing a consistently high standard of 
service’ (p. 2).1 In addition, Commissioner Harris is committed 
to ‘holding the organisation to account for our performance 
against this plan. This development of a strong performance 
culture will be key to ensuring the long-term delivery of 
progressive organisational change and professional victim 
focussed services’ (p. 2).1
Ciara H Guiney
1 An Garda Síochána Strategic Planning Unit (2019) An Garda 
Síochána policing plan 2019. Dublin: An Garda Síochána. https://
www.drugsandalcohol.ie/31128/
2 An Garda Síochána (2019) An Garda Síochána strategy statement 
2019–2021. Dublin: An Garda Síochána. Available online at: https://
www.garda.ie/en/about-us/publications/policing-plans/strategy/
garda-strategy-statement-2019-2021-2-1-20.pdf
3 Government of Ireland (2019) A policing service for the future: 
implementing the Report of the Commission on the Future of 
Policing in Ireland. Dublin: Stationery Office. Available online at: 
https://www.garda.ie/en/about-us/a-policing-service-for-the-
future/implementation-plan.pdf
4 An Garda Síochána (2019) An Garda Síochána people strategy 
2019–2021. Dublin: An Garda Síochána. Available online at: https://
www.garda.ie/en/about-us/publications/policing-plans/strategy/
ags_people-strategy_2019_2021.pdf
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Recording of migrant 
and ethnic identity 
in the European 
Treatment Demand 
Indicator
In November 2019, a study on registering ethnicity and 
migration in the European Treatment Demand Indicator (TDI) 
registry was published in the Journal of Ethnicity in Substance 
Abuse.1 According to international evidence, migrants and 
ethnic minorities (MEM) are a subpopulation who are both 
disproportionately affected by drug use and disadvantaged in 
accessing treatment. However, as the study author notes, data 
on treatment demand of MEM in Europe are currently limited. 
The study (a) discusses the importance of recording migration 
and ethnicity in the TDI along with its risks; (b) analyses current 
treatment trends from the 2014 national TDI reports; and (c) 
draws on survey responses from 19 national TDI focal points 
to identify indicators used and to make recommendations for 
improvement.
Treatment demand trends among MEM
• Populations with high prevalence: Twenty national reports 
specified MEM populations with high prevalence. Eight 
countries did not single out specific populations, often 
citing insufficient data. Highlighted in the reports as most 
vulnerable to problem drug use were (a) non-nationals; (b) 
Roma populations; and (c) people of Russian ethnicity.
• Drug treatment demand and social correlates: Only 
50% of the reports included statistics on drug treatment 
demand among MEM, predominantly by nationality. 
However, they were often reported without further details, 
such as comparisons with the general population or other 
social correlates. An exception is the Irish report featuring 
an in-depth analysis of Irish Travellers’ drug treatment 
demand. Where social correlates for drug use among 
MEM are reported, homelessness, unemployment, low 
educational attainment, and being undocumented are most 
frequently mentioned, albeit without being analysed with 
TDI data.
• Drug-related crime: Eighteen reports contained figures on 
MEM populations and drug-related crime. Non-nationals 
represented a high percentage of those imprisoned for 
drug-related crime in some countries (e.g. 39% in Finland), 
but a low percentage in others (e.g. 8% in Greece). Yet 
trends are difficult to identify due to a lack of uniform, in-
depth reporting.
• Health and risk behaviours: Some countries reported an 
overrepresentation of non-nationals among drug users 
who tested positive for infectious diseases and those who 
engaged in high-risk behaviours such as injecting.
• Access: While all 2014 reports mentioned their national 
strategies to widen treatment access, only four reports 
(Ireland, United Kingdom (UK), Germany, and Luxembourg) 
mentioned MEM in the context of accessibility.
Current TDI migration and ethnicity recording
The TDI Protocol 3.0 (2012) does not require the recording of 
nationality. While the recording of ethnicity and nationality 
is legal and General Data Protection Regulation (GDPR)-
compliant, 18 member states or more insufficiently regulate 
the collecting of these sensitive data, contributing to a taboo 
around their recording. 
The study’s survey, following consultation with member state 
experts, revealed:
• Out of 19 respondents, three stated as not recording 
migration data, or only having data on the total of non-
nationals.
• Nationality was most frequently recorded (10 respondents), 
along with birthplace (6), EU/non-EU status (5), ethnicity (5), 
nationality at birth (4), parent birthplace/nationality (1), and 
language (1).
• 15 respondents used two or more indicators.
• All respondents stated that coverage was a problem, 
regarding service participation in the TDI in general and the 
lack of individual-level data for some countries.
• The most common method of recording ethnicity and 
migration was via service providers. Four respondents 
reported additionally or exclusively allowing open-ended 
answers.
Recommendation and conclusions
The study concluded that the potential of the TDI dataset to 
capture treatment demand trends and inform coordinated 
policymaking currently remains unused for the subpopulations 
of MEM. Given the international evidence that MEM often 
show disparities in drug treatment need and access, data 
on their characteristics and requirements are vital for equal 
opportunities for the recovery of MEM populations.
Recommendations by national experts to improve MEM 
recording included:
• Requiring reliable ethnicity and migration indicators 
in the TDI Protocol (n=5): While nationality is currently 
recorded by 30% of member states, the author argued for 
adding mother’s birthplace and language-related and self-
identified ethnicity indicators to allow for a more complex 
and self-determined representation of service users’ 
backgrounds.
• Conducting in-depth intersectional analyses of MEM 
treatment demand with TDI data (n=2): Migration and 
ethnicity variables must be examined in context with 
social correlates (e.g. gender, education, employment, 
etc.) to avoid one-dimensional and potentially further 
stigmatising conclusions. Such analyses would enable a 
more considered representation of the characteristics and 
causalities of MEM’s treatment demand.
• Using unique identifiers to allow individual-level insights 
and database linkage (n=3): This could be a TDI-specific, 
pseudo-anonymised identifier, as national identifiers would 
not be available to undocumented migrants.
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Migrant and ethnic identity   
continued
However, while recording ethnicity and migration status 
has the potential to increase equality, it also bears risks and 
concerns regarding privacy, self-determination, and potential 
misuse of such sensitive data to further stigmatise vulnerable 
subpopulations. Therefore, the author argues for clearly stating 
in the TDI the purpose of data collection as increasing equality 
and protecting the rights of data subjects (following the UK’s 
example). Furthermore, practising informed consent by clearly 
communicating to service users is important. Eurobarometer 
results show that this could encourage voluntary disclosure 
of ethnicity and migration identities and preclude fear of 
discrimination.2
The Irish TDI register has included questions on ethnicity since 
2007 and currently also features questions on main language 
and country of birth. Along with the UK, Ireland is the only EU 
country which records ethnicity data with the specified goal 
of enacting positive measures, illustrating the feasibility of the 
current study’s recommendations.
Britta Thiemt
1 De Kock C (2019) Migration and ethnicity related indicators in 
European drug treatment demand (TDI) registries. J Ethn Subst 
Abuse, 5 Nov: 1–27. doi: 10.1080/15332640.2019.1664962.
2 Makkonen T (2016) European handbook on equality data: 2016 
revision. Luxembourg: Publications Office of the European 
Union. Available online at: https://ec.europa.eu/newsroom/just/
document.cfm?action=display&doc_id=43205
Seminar on 
increasing 
engagement of 
Travellers within 
addiction services
Pavee Point Traveller and Roma Centre held a seminar on 
increasing the engagement of Travellers within the addiction 
services on 13 November 2019.1 The aim of the seminar was to 
improve engagement between Travellers and State agencies, 
present examples of positive work and models of good 
practice, and identify key recommendations in relation to 
Travellers and problem drug use in preparation for the review 
of the current national drugs strategy.
The seminar was chaired by Martin Collins (co-chair of Pavee 
Point) and opened by Minister of State with responsibility for 
Health Promotion and the National Drugs Strategy, Catherine 
Byrne TD. The following speakers presented on the day. Dr 
Anne Marie Carew from the Health Research Board presented 
trends in drug treatment data focusing on Travellers. Dr 
Jane Mulcahy from University College Cork spoke on the 
wide-reaching effects of intergenerational trauma due to 
discrimination on addiction. Anna Quigley from CityWide 
Drugs Crisis Campaign discussed the challenges of working 
in the community, while John Paul Collins and Corrine Doyle 
from Pavee Point Traveller and Roma Centre gave an in-depth 
presentation on the organisation. Subsequently, Doreen 
Carpenter of the Clondalkin Travellers Development Group 
and Jennifer Clancy of the Clondalkin Drug and Alcohol Task 
Force presented the Clondalkin Model as a good example of 
interagency practice. Finally, Michael Cawley, the Traveller and 
Client Coordinator at Coolmine Therapeutic Centre, spoke 
eloquently of his experience in the addiction services.
Suzi Lyons
1 For further information on the seminar, visit: https://www.
paveepoint.ie/national-drugs-strategy-failing-travellers/
Dr Anne Marie Carew,  
speaking at the 
seminar on Travellers' 
engagement with 
addiction services
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Participants at the 
seminar on Travellers’ 
engagement with 
addiction services in 
November 2019 at Pavee 
Point Traveller and Roma 
Centre
European Prevention 
Curriculum 
Handbook
The European Prevention Curriculum (EUPC) is a programme 
of training, the primary goal of which is ‘to reduce the health, 
social and economic problems associated with substance 
use by building international prevention capacity through the 
expansion of the European professional prevention workforce’ 
(p. 10).1 It originated as an American training programme, the 
Universal Prevention Curriculum (UPC), and underwent a 
rigorous adaptation process to ensure its suitability for the 
European context.2 The latest output from this work is the EUPC 
Handbook, published by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA).1,3
The primary purpose of the handbook is to provide reference 
material for the EUPC training courses for local and regional 
decision-makers, opinion-makers, and policymakers working in 
the field of substance use prevention across Europe. However, 
the handbook offers a valuable introduction to prevention 
science and science-based interventions, which should be of 
use to all stakeholders with an interest in the field.
Necessity for EUPC
In his foreword to the report, Alexis Goosdeel, EMCDDA 
Director, emphasises the need for a more science-based 
approach to prevention across Europe. While progress has 
been made in ‘developing responsible and science-based 
prevention interventions’, he notes that:
Nevertheless, many challenges remain and, in 
many countries, we continue to see prevention 
practices for which there is little or no evidence 
of effectiveness being implemented in both school 
and community settings. In the worst cases, poorly 
designed prevention interventions may even cause 
harm. (p. 7)
It is within this context that the EMCDDA supports the 
development and delivery of high-quality training for those 
working in the sector, where the handbook is seen as a key 
component of this work.
Content of EUPC handbook
The handbook is divided into two broad parts: the first part 
focuses on the general concepts underpinning effective 
prevention, while the second part explores prevention 
approaches in different settings. Based on an outline given in 
the introduction to the handbook, there are four substantive 
chapters in the first part (p. 14). They cover the following:
• The link between epidemiology and aetiological theories: 
It offers an understanding of the role prevention can play in 
addressing the development of substance use disorders.
• Common theories used by prevention scientists 
when developing and evaluating effective prevention 
interventions and policies: It is argued that awareness 
of these theories is important for understanding which 
elements are necessary or useful in developing and/or 
adapting prevention interventions in different contexts and 
settings.
• Evidence-based prevention interventions and policies: It 
focuses on the United Nations Office on Drugs and Crime’s 
(UNODC) International Standards on Drug Use Prevention4 
and the EMCDDA’s European Drug Prevention Quality 
Standards (EDPQS).5 This chapter also contrasts evidence-
based approaches, which advocate the use of standardised 
interventions, with tailor-made approaches, which are 
often based on professional experience and presented 
needs. This discussion highlights how different approaches 
are used across Europe.
• Monitoring and evaluation: It provides an overview of 
different types of evaluation research that can be used to 
monitor or evaluate the effects of an intervention or policy.
The second part of the handbook focuses on prevention in 
different settings. The areas covered include family; school 
and workplace; environment; media; and community. The 
challenges of delivering prevention interventions in each setting 
are discussed, as well as a focus on evidence-based practices 
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National Drug 
Prevention and 
Education Forum
On 13 June 2019, a National Drug Prevention and Education 
Forum was held in Dublin. The forum was the first event 
organised by the Drug and Alcohol Education Workers Forum 
(DAEWF), a network of prevention and education workers in 
Ireland. The network was set up to pursue joint pieces of work 
in the field and to promote a more integrated and best practice 
approach to prevention and education in Ireland.
A rapporteur’s report of the forum has been published.1 It was 
launched on 10 December 2019 with contributions from Dr 
Bobby Smyth, consultant child and adolescent psychiatrist; 
Senator Aodhán Ó Ríordáin of the Labour Party; and report 
author Dr Laura O’Reilly from Ballymun Youth Action Project.
Rapporteur’s report
The rapporteur’s report outlines the presentations made at 
the forum and captures the key components of the delegates’ 
discussions. The following presentations were made at the 
forum:
• ‘Drug education and prevention in Ireland: past, present 
and future?’ by Dr Clay Darcy, Drug Education and 
Prevention Development Officer, Crosscare Youth Service 
and the Bray Drugs Awareness Forum.
• ‘Supporting a professional prevention workforce in 
Europe’ by Gregor Burkhart, Principal Scientific Analyst for 
Prevention, European Monitoring Centre for Drugs and Drug 
Addiction.
• ‘The School Health and Alcohol Harm Reduction Project 
(SHAHRP) and Steps Towards Alcohol Misuse Prevention 
Programme (STAMPP) 2004–2019’ by Michael McKay, Royal 
College of Surgeons in Ireland.
• ‘Planet Youth in the west of Ireland’ by Orla Walshe, Project 
Development Worker, Western Region Drug and Alcohol 
Task Force.
Key components and recommendations
Based on these presentations and the forum’s discussions, 
the report makes a set of recommendations for how drug 
prevention and education should move forward. A selection of 
key findings from the day and the associated recommendations 
are outlined below.
Clarification of drug prevention and drug education
A recurring theme throughout the report was the perception 
that there is a lack of understanding among stakeholders about 
prevention and education strategies and how they differ from 
each other. The report argues that this impacts on policy, 
practice, monitoring, and evaluation in the field – it results in 
‘incoherence regarding prevention and education objectives 
and outcomes and a lack of evidence showing prevention and 
education effectiveness’ (p. 5). To improve clarity, the report 
recommends that when working in this field stakeholders 
(local and regional drug and alcohol task forces, funders, 
policymakers, etc.) should adopt an agreed categorisation2 of 
the differing elements – prevention, education, information 
provision, and harm reduction (see Table 1). 
Professionalisation of prevention and education sector
The report indicates broad agreement among delegates that 
the prevention and education sector would benefit from being 
more professionalised. It was described as a workforce that 
exhibited diversity in its ‘skills, knowledge, background, training 
role definition and description’ (p. 13), and that in general there 
was a lack of information on what training workers possess. 
The report notes that ‘the application of evidenced based 
principles and a trained and accredited prevention workforce 
like the treatment and rehabilitation sector would result in 
an improved prevention workforce with competencies and 
expertise in prevention principles, theories and practice’ 
(p. 13). Two key recommendations for delivering a more 
professionalised workforce were identified:
• Prevention and education workers should be provided with 
training, qualifications, and opportunities to upskill. To meet 
this need, it is recommended that the prevention training 
European Prevention Curriculum 
Handbook   continued
across the settings in Europe and a more detailed discussion of 
interventions.
Lucy Dillon
1 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) (2019) European prevention curriculum: a handbook for 
decision-makers, opinion-makers and policy-makers in science-
based prevention of substance use. Luxembourg: Publications 
Office of the European Union. https://www.drugsandalcohol.
ie/31119/
2 The EUPC was developed by a European project entitled UPC-
Adapt. It was co-funded by the EMCDDA and the European 
Commission. Eleven partners from nine European countries 
cooperated on the project and adapted the UPC to suit a 
European audience. The UPC was originally developed by Applied 
Prevention Science International (APSI) with funding from the 
US Department of State to the Colombo Plan Drug Advisory 
Programme. Adaptation of the UPC for the European context was 
based on the guidelines of the European Prevention Standards 
Partnership on adaptation and dissemination of quality standards 
in different contexts (EDPQS Toolkit 4). For further information on 
UPC-Adapt, visit: http://upc-adapt.eu/
3 The handbook is intended for training purposes only by individuals 
who have completed a required course. The criteria for delivery 
of EUPC courses can be found at: http://www.emcdda.europa.
eu/best-practice/european-prevention-curriculum. Details of 
current training providers are also found on the website. Email 
EUPC@emcdda.europa.eu for related enquiries and feedback.
4 United Nations Office on Drugs and Crime (UNODC) (2018) 
International Standards on Drug Use Prevention. 2nd edn. Vienna: 
UNODC, World Health Organization.  
https://www.drugsandalcohol.ie/30048/
5 European Drug Prevention Partnership (2015) European Drug 
Prevention Quality Standards (EDPQS) Toolkits 1–4. Liverpool: 
Centre for Public Health, Liverpool John Moores University and 
EMCDDA. https://www.drugsandalcohol.ie/24582/
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Drug information Drug education Drug prevention Harm reduction
• Descriptions of drugs
• Descriptions of drug 
effects
• Once-off talks or 
presentations
• Materials such as: 
leaflets, posters, films, 
worksheets, handouts, 
booklets and awareness 
campaigns
• Systematic process of 
acquiring knowledge 
about drugs that leads to 
understanding
• Drug education should 
be developmental and 
have achievable learning 
outcomes
• Should help equip the 
participant learner to 
traverse social contexts 
where drugs are available 
and/or commonly used
• Interventions that work to 
prevent/delay drug use
• Interventions that 
promote the cessation of 
drug use, and/or aim to 
reduce harms of drug use
• Drug prevention is not 
always about drugs, it may 
focus on sociocultural or 
familial contexts
• Interventions that work to 
reduce the harm caused 
by drug use or that work 
toward reducing or 
cessation
• Includes needle exchange 
services, supervised 
injection centres, drug 
testing, and/or other 
interventions by medical 
practitioners
syllabus, the European Universal Prevention Curriculum 
(EUPC), should be explored for adaptation and rollout in 
Ireland.
• A professional body should be established that would agree 
on and have oversight of core competencies in this sector.
Evaluation 
Evidencing the impact of prevention and education strategies 
was identified by the forum as challenging. It was argued that 
there is a need to challenge the perception that education 
and prevention do not work. The report suggests that the lack 
of evidence may be attributed to a shortage of appropriate 
mechanisms and frameworks available to prevention and 
education workers to evaluate their work. This is further 
compounded by a lack of appropriate evaluation skills on 
the part of the practitioner. The report recommends using 
the categorisation outlined in Table 1 ‘to give rise to simpler, 
more accurate measurement of outcomes’ (p. 14). It was also 
recommended that a national lead or organisation be given 
responsibility for the monitoring and evaluation of prevention 
and education initiatives.
Prevention and education on a strategic level
There was a perception at the forum that from a strategic point 
of view prevention and education has become increasingly 
undervalued and lacking in recognition since 2010. Concern 
was expressed about a ‘lack of a long-term vision for the 
effective delivery of prevention and education from the 
top down’ (p. 11). Recommendations in the report therefore 
included that the sector makes a submission to the mid-term 
review of the national drugs strategy to raise the visibility of 
its work; and more broadly that the sector works in closer 
collaboration with Government Departments and State 
agencies. Community mobilisation was identified as a tool that 
could be used to create opportunities for raising the profile of 
prevention and education work.
Drug and Alcohol Education Workers Forum
The report cites an ‘overwhelming consensus’ (p. 14) on the 
positive role of the DAEWF within the substance use field. It 
is recommended that its mandate be reviewed and further 
developed. Among the recommendations made for this were:
• Regular DAEWF meetings should be held and its 
membership expanded.
• Existing collaborations should be built on and new ones 
developed with relevant agencies and departments.
• The Manual in quality standards in substance use 
education, produced in 2007 by the Drug Education 
Workers Forum (DEWF),3 should be reviewed.
• Such standards should be used and that good practice 
guidelines in harm reduction, education, information, and 
prevention should be developed.
• SHAHRP delivery in Ireland should be developed, adapted, 
implemented, and reviewed.
Overall, this report identifies key limitations facing the drug 
education and prevention sector in Ireland. However, it also 
indicates a move on the part of the sector to raise its profile 
and address these limitations. For example, it seeks clarity 
through an audit of what programmes are being delivered 
in Ireland and where; it suggests improving the quality of 
evaluation of interventions; and has a clear focus on the need 
to address the professionalisation of its labour force.
Lucy Dillon
1 O’Reilly L (2019) National Drug Prevention and Education Forum, 
13th June 2019, Dublin. Rapporteur’s report. Dublin: Drug and 
Alcohol Education Workers Forum.  
https://www.drugsandalcohol.ie/31425/
2 Darcy C (2018) The precarious position of drug education workers 
in Ireland. Economic and Social Review, 49(3): 361–372. https://
www.drugsandalcohol.ie/29721/
3 Butler E, Smith S, Rowley C and Keane R (eds) (2007) A manual 
in quality standards in substance use education. Dublin: Drug 
Education Workers Forum.  
https://www.drugsandalcohol.ie/6339/
Table 1: Categorisation of drug information, drug education, drug prevention, and harm reduction, as proposed by Darcy (2018)
Source: National Drug Prevention and Education Forum: Rapporteur’s report, p. 5
National Drug Prevention and 
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EUSPR conference 
– promoting 
multidisciplinary 
work in prevention
The 10th Conference of the European Society for Prevention 
Research (EUSPR) was held in Ghent, Belgium, during 16–18 
September 2019. EUSPR was established to promote ‘the 
development of prevention science, and its application to 
practice so as to promote human health and well-being 
through high quality research, evidence based interventions, 
policies and practices’.1 The cornerstones of its work are 
a cross-disciplinary network of scientists, policymakers, 
and practitioners; the development of methodologies; the 
promotion of higher education and career development in 
prevention; and the implementation of research.
The conference theme for 2019 was ‘Looking over the wall 
– promoting multidisciplinary work in prevention’. Speakers 
represented the international community working in the area of 
prevention. Posters and parallel session presentations covered 
a wide range of topics, including programme evaluations, 
methodological approaches, and broader debates on the role 
and value of prevention. Preventing substance use was just 
one of the behaviours addressed in the conference. A book of 
abstracts from the conference is available online.2
Lucy Dillon
1 For further information on EUSPR and the conference, visit http://
www.euspr.org
2 European Society for Prevention Research (2019) Looking over 
the wall: promoting multidisciplinary work in prevention. 10th 
EUSPR Conference and Members’ Meeting, 16–18 September 2019, 
Ghent, Belgium. Programme and Book of Abstracts. https://www.
drugsandalcohol.ie/31353/
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UPDATES
Recent publications
PREVALENCE AND CURRENT SITUATION
Drinking patterns and the distribution of alcohol-related harms 
in Ireland: evidence for the prevention paradox
O’Dwyer C, Mongan D, Millar S, Rackard M, Galvin B, Long J, et al. 
(2019) BMC Public Health, 19(1): 1323.
https://www.drugsandalcohol.ie/31239/ 
In this study we explored the prevention paradox in the Irish 
population by comparing alcohol-dependent drinkers (high-risk) 
to low-risk drinkers and non-dependent drinkers who engage in 
heavy episodic drinking (HED).
Our results indicate that the majority of alcohol consumption 
and related harms in the Irish population are accounted for by 
low- and moderate-risk drinkers, and specifically by those who 
engage in heavy episodic drinking. A population-based approach 
to reducing alcohol-related harm is most appropriate in the Irish 
context. Immediate implementation of the measures in the Public 
Health (Alcohol) Act (2018) is necessary to reduce alcohol-related 
harm in Ireland.
Profile of fire fatalities in Ireland using coronial data
Doyle A, Lyons S and Lynn E (2019) Fire Safety Journal, 110: 102892.
https://www.drugsandalcohol.ie/31208/ 
For the first time in the Republic of Ireland, analysis using coronial 
data describes all fire-related fatalities occurring during the years 
2014–2016. 
Alcohol features prominently with alcohol present on toxicology 
for 54 (51%) fatalities. A Blood Alcohol Concentration (BAC) of 
at least 160 mg of alcohol per 100 mL of blood (mg/100 ml) was 
present in 35 fatalities (33% of all fatalities) and, of those, the 
majority were male and in the 35–59 years age group. The high 
BAC levels in a significant number of fire fatalities draws attention 
to the negative impact of alcohol on fire-related mortality.
National Drugs Library
Acceptability and accuracy of oral fluid drug testing for patients 
on methadone maintenance
O’Callaghan ME, Regan L, Wilson M, Byrne E, Hollywood B, O’Kelly 
F, et al. (2019) Irish Journal of Medical Science, Early online.
https://www.drugsandalcohol.ie/31236/ 
This project aims to evaluate the accuracy and acceptability of 
oral fluid testing for patients on methadone maintenance and also 
gather patient views on their treatment.
This study presents evidence that oral fluid testing is acceptable 
to most patients. While oral fluid testing was inferior to urine 
testing for benzodiazepines, it may have an adjunctive role to play 
in methadone maintenance provision. Patients reported more 
negative than positive aspects of methadone maintenance.
The seroprevalence of untreated chronic hepatitis C virus 
(HCV) infection and associated risk factors in male Irish 
prisoners: a cross-sectional study, 2017
Crowley D, Lambert JS, Betts-Symonds G, Cullen W, Keevans M, 
Kelly E, et al. (2019) Eurosurveillance, 24(14): 1800369.
https://www.drugsandalcohol.ie/31182/ 
We aimed to estimate the seroprevalence of untreated chronic 
HCV infection and to identify associated risk factors in an Irish 
male prison.
The level of untreated chronic HCV infection in Irish prisons is 
high, with IDU [injecting drug use] the main associated risk.
Incidence and risk factors for invasive pneumococcal disease in 
HIV-positive individuals in the era of highly active antiretroviral 
therapy
Sadlier C, O’Connell S, Kelleher M and Bergin C (2019) International 
Journal of STD & AIDS, 30(5): 472–478.
https://www.drugsandalcohol.ie/31260/ 
The aim of this study was to measure temporal trends in incidence 
and risk factors for IPD (defined as culture of Streptococcus 
pneumoniae from blood, cerebrospinal fluid or both) in a cohort 
of HIV-positive patients attending an ambulatory HIV care centre 
in Dublin, Ireland over a 10-year period 2006–2015. Incidence of 
IPD was determined as events per 100,000 person-years' follow-
up. Poisson regression was used to assess linear trend in incidence 
over time.
HIV-positive individuals remain at greater risk of IPD compared to 
the general population. Pneumococcal vaccine should be seen as 
a priority to ensure optimal protection for HIV-positive patients.
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Cannabis use and associated health problems – what’s the 
harm?
Smyth BP, O’Farrell A and Daly A (2019) Irish Medical Journal, 112(9): 
1000.
https://www.drugsandalcohol.ie/31216/ 
We sought to describe the changing pattern of cannabis use and 
cannabis related health harms. 
A concerted public health response is required to address 
escalating cannabis related health harms which have coincided 
with the arrival of more potent cannabis.
Hepatitis C prevalence and management among patients 
receiving opioid substitution treatment in general practice in 
Ireland: baseline data from a feasibility study
Murtagh R, Swan D, O’Connor E, McCombe G, Lambert JS, 
Avramovic G, et al. (2018) Interact J Med Res, 7(2): e10313.
https://www.drugsandalcohol.ie/30874/
We aimed to examine whether patients receiving opioid 
substitution therapy in primary care practices in Ireland were 
receiving guideline-adherent care regarding HCV [hepatitis 
C virus] screening. Ireland has developed a model of care for 
delivering opioid substitution treatment in the primary care 
setting. We conducted this study given the shift of providing care 
for PWID [people who inject drugs] from secondary to primary 
care settings, in light of current guidelines aimed at scaling up 
interventions to reduce chronic HCV infection and associated 
mortality.With general practice and primary care playing an 
increased role in HCV care, this study highlights the importance 
of prioritizing the development and evaluation of real-world 
clinical solutions that support patients from diagnosis to treatment 
completion.
Hepatitis C virus screening and treatment in Irish prisons 
from a governor and prison officer perspective – a qualitative 
exploration
Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS and Cullen 
W (2018) Health & Justice, 6(1): 23.
https://www.drugsandalcohol.ie/30873/ 
We aim to identify the barriers and enablers to HCV screening and 
treatment in Irish prisons and inform the implementation of a HCV 
screening program within the Irish Prison Services (IPS).
Upscaling HCV management in prisons requires an in-depth 
understanding of all barriers and facilitators to HCV screening and 
treatment. Engaging prison officers in the planning and delivery 
of health care initiatives is a key strategy to optimising the public 
health opportunity that prisons provide.
Deaths in custody in the Irish prison service: 5-year 
retrospective study of drug toxicology and unnatural deaths
Iqtidar M, Sharma K, Mullaney R, Kelly E, Keevans M, Cullinane M, et 
al. (2018) BJPsych Open, 4(5): 401–403.
https://www.drugsandalcohol.ie/30871/ 
Deaths in Irish prisons between 2009 and 2014 were 
retrospectively analysed using coroner's findings, including post-
mortem toxicology.
There were 69 deaths in custody, 38 of which met inclusion 
criteria. All deaths by overdose (16) were positive for illicit drugs; 
53% of deaths (8 of 15) due to hanging were also positive for 
illicit drugs, and 29% of deaths (2 of 7) from other causes were 
toxicology positive. In conclusion, 26 unnatural deaths (68%) were 
associated with use of illicit drugs, which are a major contributory 
factor to deaths of prisoners.
Alcohol use disorder and comorbid depression: a randomized 
controlled trial investigating the effectiveness of supportive 
text messages in aiding recovery
O’Reilly H, Hagerty A, O’Donnell S, Farrell A, Hartnett D, Murphy E, 
et al. (2019) Alcohol and Alcoholism, 54(5): 551–558.
https://www.drugsandalcohol.ie/30884/ 
The aim of this randomized controlled trial was to examine 
the impact of daily supportive text messages over a 6-month 
treatment period on mood and alcohol consumption in individuals 
with a dual diagnosis of alcohol use disorder (AUD) and depression 
following completion of an inpatient treatment programme.
Supportive text messages provide an early initial benefit in 
decreasing symptoms of depression and stress, with a further 
positive impact on alcohol consumption following a longer 
treatment period. Benefits did not persist six months after the 
intervention ended.
Online gaming and gaming disorder: more than just a trivial 
pursuit
Columb D, Griffiths MD and O’Gara C (2019) Irish Journal of 
Psychological Medicine, Early online.
https://www.drugsandalcohol.ie/30885/ 
This article briefly examines online gaming and describes the 
characteristics of gaming disorder. Some features of online gaming 
that have addictive potential and similarities to other addictive 
behaviours such as gambling disorder are discussed. Finally, the 
article examines treatment options available for gaming disorder 
and treatment going forward from an Irish perspective.
Recanting of previous reports of alcohol consumption within 
a large-scale clustered randomised control trial
Percy A, Agus A, Cole J, Doherty P, Foxcroft D, Harvey S, et al. 
(2019) Prevention Science, 20(6): 844–851.
https://www.drugsandalcohol.ie/30889/ 
The aim of this study was to examine the extent of recanting 
(inconsistencies in reporting of lifetime alcohol use) and its 
impact on the assessment of primary outcomes within a large-
scale alcohol prevention trial.
While differential rates of recanting have the potential to 
undermine the analysis of prevention trial outcomes, recanting 
is easy to identify and control for within trial primary outcome 
analyses. Adjusting for recanting should be considered as an 
additional sensitivity test within prevention trials.
Recent publications   continued
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Impact of carers' smoking status on childhood obesity in the 
Growing up in Ireland Cohort Study
Sunday S and Kabir Z (2019) International Journal of 
Environmental Research and Public Health, 16(15): 2759.
https://www.drugsandalcohol.ie/30908/ 
This study aimed to assess the impact of carers' smoking status 
on childhood obesity in a cohort of children enrolled in the 
Growing up in Ireland (GUI) study. Participants from the GUI 
infant cohort were categorized into four groups based on 
their exposure status: Neither caregiver smoked (60.4%), only 
primary caregiver smoked (13.4%), both caregivers smoked 
(10.9%). 
Exposure to primary carers' smoking (98% are biological 
mothers) was found to be significantly associated with 
childhood overweight/obesity at age three (Odds Ratio: 1.30, 
95% CI: 1.17-1.46) and at age five (OR: 1.31, 95% CI: 1.16-1.49). 
Exposure to both carers' smoking status was significantly 
associated with increased odds of childhood overweight/
obesity across both waves. These findings emphasize the 
health burden of childhood obesity that may be attributable to 
maternal smoking postnatally and through early childhood in 
Ireland.
The emergence of new psychoactive substance (NPS) 
benzodiazepines. A survey of their prevalence in opioid 
substitution patients using LC-MS
McNamara S, Stokes S and Nolan J (2019) Irish Medical Journal, 
112(7): 970.
https://www.drugsandalcohol.ie/30910/ 
200 urine samples from patients attending the HSE National 
Drug Treatment Centre (NDTC) who are monitored on a regular 
basis for drug and alcohol use and which tested positive 
for benzodiazepine class drugs by immunoassay screening 
were subjected to confirmatory analysis to determine what 
Benzodiazepine drugs were present and to see if etizolam or 
other new benzodiazepines are being used in the addiction 
population currently.
Benzodiazepine prescription and use is common in the 
addiction population. Of significance we found evidence of 
consumption of an illicit new psychoactive benzodiazepine, 
Etizolam.
Towards a Tobacco Free Ireland – scaling up and 
strengthening quit smoking behaviour at population level
Petty-Saphon N and Kavanagh P (2020) Irish Journal of Medical 
Science, 189(1): 3–10.
https://www.drugsandalcohol.ie/30938/ 
A secondary analysis of Healthy Ireland 2015 was undertaken to 
identify determinants of smoking cessation attempts and the 
use of smoking cessation aids in the general adult population in 
Ireland.
This study highlights the need to strengthen smoking cessation 
in Ireland to increase the number of smokers that successfully 
quit and achieve a Tobacco Free Ireland. The development and 
implementation of National Clinical Guidelines for the Diagnosis 
and Treatment of Tobacco Addiction will play a key role in this.
Romantic attraction and substance use in 15-year-old 
adolescents from eight European countries
Költő A, Cosma A, Young H, Moreau N, Pavlova D, Tesler R, et 
al. (2019) International Journal of Environmental Research and 
Public Health, 16(17): 3063.
https://www.drugsandalcohol.ie/30964/ 
Sexual minority youth are at higher risk of substance use than 
heterosexual youth. However, most evidence in this area is 
from North America, and it is unclear whether the findings 
can be generalized to other cultures and countries. In this 
investigation, we used data from the 2014 Health Behaviour in 
School-aged Children (HBSC) study to compare substance use 
in same- and both-gender attracted 15-year-old adolescents 
from eight European countries (n = 14,545) to that of their peers 
who reported opposite-gender attraction or have not been 
romantically attracted to anyone.
The results suggest that sexual minority stigma (and love 
on its own) may contribute to higher substance use among 
adolescents in European countries.
The administration of naloxone – social care worker 
perspectives and experiences
Deacy JJP and Houghton F (2019) Irish Medical Journal, 112(7): 
975.
https://www.drugsandalcohol.ie/30911/ 
Opioid addiction in many countries has risen considerably in 
recent years, leading to the increasing use of terms such as the 
Opioid Crisis and the Opioid Epidemic. Substantial international 
attention has focused on this issue following significant 
increases in opioid related overdoses resulting in death. This 
phenomenon has been particularly marked in countries such 
as the USA and the UK. It is estimated that in 2015 Europe 
experienced 8,441 deaths from opioid overdose. The European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
notes that Ireland has also experienced a significant rise in 
opioid and methadone related deaths in recent years. Evidence 
suggests that on average heroin users will overdose three times 
in their lifetime, and that one in two heroin addicts will die from 
an overdose.
Alcohol use, regular use, disorder and remission from use 
disorders in Northern Ireland: a prevalence study
Bunting B and Bharat C (2019) Addiction Research & Theory, 
27(4): 347–353.
https://www.drugsandalcohol.ie/31109/ 
This study presents prevalence estimates and ages of onset for 
alcohol use, regular use, use disorders and remission from use 
disorders in Northern Ireland, and the time for transitioning 
between these stages.
The consumption of alcohol is high within Northern Ireland 
with some 83% of the population consuming alcohol, and with 
over 90% of this group taking alcohol on a regular basis. The 
abuse of alcohol was particularly marked amongst students and 
males, with dependence showing a higher prevalence amongst 
those with the lowest level of educational attainment, and 
where the commencement of alcohol consumption was at an 
early age. Transitions between stages of lifetime alcohol use, 
regular use, and use disorders were associated with the early 
commencement of alcohol use, education, cohort use and 
being male.
Recent publications   continued
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Purchasing over the counter (OTC) medicinal products 
containing codeine – easy access, advertising, misuse and 
perceptions of medicinal risk
Wells JSG, Bergin M, Van Hout MC, McGuinness P, De Pleissis 
J, Rich E, et al. (2018) Journal of Pharmacy & Pharmaceutical 
Sciences, 21: 286–295.
https://www.drugsandalcohol.ie/31117/ 
The aim of this novel study was to report on the results of 
a survey of customers purchasing OTC codeine containing 
medicinal products at pharmacies in Ireland, South Africa and 
England; exploring use, sources of knowledge and perception 
of risks.
Codeine containing products are widely purchased and used 
in all three jurisdictions. Whilst the majority of customers 
appear to have some awareness and knowledge of risks, it 
does not materially impact on their purchasing behaviour with 
a substantial minority purchasing/using such products on a 
weekly basis. This regularity of purchase, whilst indicative of the 
popularity of such products, may also be a potential indicator 
of misuse. Future research is needed in relation to cultural and 
gendered differences and targeted information giving and harm 
reduction initiatives for safe usage of these medicinal products.
Clients' views on the importance of a nurse-led approach 
and nurse prescribing in the development of the healthy 
addiction treatment recovery model
Comiskey C, Galligan K, Flanagan J, Deegan J, Farnann J and Hall 
A (2019) Journal of Addictions Nursing, 30(3): 169–176.
https://www.drugsandalcohol.ie/31044/ 
The aims of this study were to establish from clients their 
nursing needs and to use these findings alongside an objective 
measurement of clients' health to inform the development of a 
nurse-led treatment model.
Clients articulated the role of the nurse in their physical care; 
however, unexpectedly, clients identified nurses as an essential 
source of psychological support and expressed the wish for 
the role to be expanded in terms of managing methadone 
treatment and accessing additional services and resources. 
Results contributed to the formation of the nurse-led, client 
mental-health-focused, Healthy Addiction Treatment Recovery 
Model for addiction nursing services. In terms of national 
policies, findings provided new evidence articulated by service 
users on their desire for the expansion of nurse prescribing 
in addiction services and an expansion of the role to more 
adequately address client needs.
State of the art in European addictions nursing: perspectives 
from the United Kingdom, Ireland, and the Netherlands
Clancy C, Kelly P and Loth C (2019) Journal of Addictions Nursing, 
30(3): 139–148.
https://www.drugsandalcohol.ie/31046/ 
In this article, we discuss the state of the art of addiction 
nursing in Europe. This state is viewed throughout the United 
Kingdom, Ireland, and the Netherlands and has a direct link 
to the future. Despite differences, the three countries share 
nursing values. The start of International Nurses Society in 
Addictions Nursing Ireland and the Netherlands is only the 
beginning of a new connection and cooperation Europe-wide.
'Debt on me head': a qualitative study of the experience of 
teenage cannabis users in treatment
James PD, Comiskey C and Smyth BP (2019) Journal of 
Addictions Nursing, 30(3): 211–218.
https://www.drugsandalcohol.ie/31042/ 
The aim of this study was to understand more about the 
experience of young, treatment-seeking, cannabis users.
Young cannabis users in treatment can clearly identify many 
negative aspects of their cannabis use but are particularly 
ambivalent toward cannabis. Reluctance to aim for abstinence 
is common.
Psychosocial, psychiatric and work-related risk factors 
associated with suicide in Ireland: optimised methodological 
approach of a case-control psychological autopsy study
Arensman E, Larkin C, McCarthy J, Leitao S, Corcoran P, 
Williamson E, et al. (2019) BMC Psychiatry, 19(1): 275.
https://www.drugsandalcohol.ie/31050/ 
The Suicide Support and Information System Case Control 
study (SSIS-ACE) aimed to compare psychosocial, psychiatric 
and work-related risk factors across three groups of subjects: 
suicide decedents, patients presenting to hospital with a high-
risk self-harm episode, and general practice controls.
The study allows for the investigation of consistency across 
different data sources and contributes to the methodological 
advancement of psychological autopsy research. The study will 
also inform clinical and public health practice. The comparison 
between suicide cases and controls will allow investigation of 
risk and protective factors for suicide more generally, while 
the comparison with high-risk self-harm patients will help to 
identify the factors associated specifically with a fatal outcome 
to a self-harm episode. A further enhancement is the particular 
focus on specific work-related risk factors for suicide.
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POLICY
Cost of youth tobacco-control policies in seven European 
countries
Leão T, Perelman J, Clancy L, Hoffmann L, Kinnunen JM, Mélard 
N, et al. (2019) European Journal of Public Health, Early online.
https://www.drugsandalcohol.ie/31098/ 
In this study, we aimed at estimating the costs of school 
smoking bans, school prevention programmes and non-school 
bans (smoking bans in non-educational public settings, bans 
on sales to minors and bans on point-of-sale advertising), 
implemented in Finland, Ireland, the Netherlands, Belgium, 
Germany, Italy and Portugal, for 2016.
Costs of the tobacco control policies evaluated here depend 
mainly on the number of person-hours allocated to their 
implementation, and on the scale of intervention. Non-school 
bans presented the lowest costs, and the implementation of all 
policies cost up to €36 pp for 1 year.
Better data, better policy and better lives: a call for 
improved drug monitoring and concerted responses
Comiskey C, Bretteville-Jensen AL, Bergeron H, Bühringer G, 
Dargan P, Davoli M, et al. (2020) Addiction, 115(2): 199–200.
https://www.drugsandalcohol.ie/30863/ 
[Editorial] With the breadth of new psychoactive substances 
and international policy changes, an analysis of specific 
responses in all areas of drug supply and demand is beyond 
the resources of a single country. The Scientific Committee 
of the EMCDDA calls for a strengthening of global monitoring 
and evidence synthesis and a renewed vigour in collaborative 
efforts to expand training, research and the quality and 
comparability of data across Europe and beyond.
RESPONSES
Hepcare Europe – bridging the gap in the treatment of 
hepatitis C: study protocol
Swan D, Cullen W, Macías J, Oprea C, Story A, Surey J, et al. 
(2018) Expert Review of Gastroenterology & Hepatology, 12(3): 
303–314.
https://www.drugsandalcohol.ie/30877/ 
This paper describes the Hepcare Europe project, a 
collaboration between five institutions across four member 
states (Ireland, UK, Spain, Romania), to develop, implement and 
evaluate interventions to improve the identification, evaluation 
and treatment of HCV among PWID [people who inject drugs].
Hepcare has the potential to make an important impact on 
patient care for marginalised populations who might otherwise 
go undiagnosed and untreated. Lessons learned from the study 
can be incorporated into national and European guidelines and 
strategies for HCV.
Does an adapted Dialectical Behaviour Therapy skills training 
programme result in positive outcomes for participants with 
a dual diagnosis? A mixed methods study
Flynn D, Joyce M, Spillane A, Wrigley C, Corcoran P, Hayes A, et 
al. (2019) Addiction Science & Clinical Practice, 14(1): 28.
https://www.drugsandalcohol.ie/30939/ 
It has been hypothesised that the skills training, which is a facet 
of the full DBT [dialectical behaviour therapy] programme, 
might be effective for people with severe emotional 
dysregulation and other co-occurring conditions, but who do 
not meet the criteria for BPD [borderline personality disorder]. 
However, there is limited research on standalone DBT skills 
training for people with substance misuse and emotional 
dysregulation.
This DBT skills training programme, adapted from standard DBT, 
showed positive results for participants and appears effective in 
treating people with co-occurring disorders. Qualitative results 
of this mixed methods study corroborate the quantitative 
results indicating that the experiences of participants have 
been positive. The study indicates that a DBT skills programme 
may provide a useful therapeutic approach to managing co-
occurring symptoms. 
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